COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF BABESIOSIS

Abstract

Described herein are compositions that comprise one or more Babesia microti antigens, one or more Babesia microti nucleic acid molecules, or one or more anti-Babesia microti antibodies and uses thereof in methods for the prophylaxis of babesiosis, the treatment of babesiosis and the monitoring of individuals undergoing prophylactic or therapeutic administration of the compositions of the invention.

Claims

1. A composition selected from the group consisting of compositions 1-112 of Tables 2-9, wherein the composition comprises each of the Bm antigens indicated as being present in the composition or one or more antigenic variants and/or antigenic fragments thereof.

2. The composition of claim 1, wherein the composition comprises one or more antigenic variant of one or more Bm antigen indicated as being present in the composition, and the sequence of the one or more variant has at least 80%, 85%, 90%, 95%, 97%, or 99% identity to the sequence of the corresponding Bm antigen indicated as being present in the composition, or an antigenic fragment thereof.

3. The composition of claim 1, wherein one or more (e.g., each) Bm antigen of the composition comprises a sequence having 100% identity to the sequence of a Bm antigen indicated as being present in the composition or an antigenic fragment thereof.

4. The composition of claim 1, further comprising a Bm antigen selected from the group consisting of Bm antigen of SEQ ID NO: 4, 8-24, 51-54, or an antigenic variant and/or antigenic fragment thereof.

5. The composition of claim 1, further comprising 1, 2, 3, 4, or 5 Bm antigens selected from the group consisting of Bm antigen(s) of SEQ ID NO: 4, 8-24, 51-54, or antigenic variant(s) and/or antigenic fragment(s) thereof.

6. A composition comprising: a Bm antigen of SEQ ID NO: 49, or an antigenic variant and/or antigenic fragment thereof; a Bm antigen of SEQ ID NO: 50, or an antigenic variant and/or antigenic fragment thereof; a Bm antigen of SEQ ID NO: 51, or an antigenic variant and/or antigenic fragment thereof; a Bm antigen of SEQ ID NO: 52, or an antigenic variant and/or antigenic fragment thereof; a Bm antigen of SEQ ID NO: 53, or an antigenic variant and/or antigenic fragment thereof; and/or a Bm antigen of SEQ ID NO: 54, or an antigenic variant and/or antigenic fragment thereof; or two or more of said Bm antigens, or antigenic variants and/or antigenic fragments thereof.

7. (canceled)

8. The composition of claim 6, comprising a Bm antigen of SEQ ID NO: 49, or an antigenic variant and/or antigenic fragment thereof; and/or a Bm antigen of SEQ ID NO: 50, or an antigenic variant and/or antigenic fragment thereof.

9. A composition comprising a nucleic acid molecule corresponding to each Bm antigen, antigenic variant, or antigenic fragment of a composition of claim 1.

10. A composition comprising an antibody that specifically binds to each Bm antigen, or antigenic variant and/or antigenic fragment thereof, of a composition of claim 1.

11. The composition of claim 1, further comprising one or more adjuvant, carrier, diluent, excipient, or preservative, and/or being formulated for administration by the oral route or a parenteral route, such as a parenteral route selected from the group consisting of the intravenous, intraperitoneal, subcutaneous, intramuscular, and topical routes.

12. (canceled)

13. A method of immunizing or conferring protective immunity against babesiosis to a subject, the method comprising administering a composition of claim 1 to the subject, and optionally wherein the etiology of babesiosis is Babesia microti.

14. The method of claim 13, wherein: (a) the subject does not experience babesiosis (b) the treatment reduces the severity of Babesia infection (e.g., parasitemia or parasite burden) upon a subsequent challenge; (c) the treatment reduces the severity of babesiosis upon a subsequent challenge; (d) the subject experiences babesiosis; (e) the treatment reduces the severity of Babesia infection (e.g., parasitemia or parasite burden); (f) the treatment reduces the severity of babesiosis; or (g) the subject experiences mild or severe babesiosis, including persistent or relapsing babesiosis.

15-20. (canceled)

21. A method of supplementing an immune response in a subject experiencing babesiosis or for treating babesiosis in a subject in need thereof, the method comprising administering a composition of claim 10 to the subject.

22-23. (canceled)

24. A method for determining whether a subject, prior to administration of a composition of claim 1, has protective immunity against Bm-induced babesiosis, the method comprising: a. applying a body fluid sample from the subject to a solid support, wherein the solid support comprises two or more Bm antigens comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-24 or 49-54, or one or more antigenic fragments thereof; b. applying an antibody detection reagent to the solid support of (a); and c. identifying the subject as likely to have protective immunity against Bm-induced babesiosis if the fluid sample from the subject is determined to have a sufficient titer of IgG antibodies that specifically react with two or more Bm antigens of (a) or antigenic fragments thereof of, that is, a titer in the fluid sample above a cutoff titer for the two or more Bm antigens.

25. A method for determining whether a subject, following administration of a composition of claim 1, has acquired protective immunity against Bm-induced babesiosis, the method comprising: a. applying a body fluid sample from the subject to a solid support, wherein the solid support comprise two or more Bm antigens comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-24 or 49-54, or one or more antigenic fragments thereof; b. applying an antibody detection reagent to the solid support of (a); and c. identifying the subject as likely to have protective immunity against Bm-induced babesiosis if the fluid sample from the subject is determined to have a sufficient titer of IgG antibodies that specifically react with two or more Bm antigens of (a) or antigenic fragments thereof of, that is, a titer in the fluid sample above a cutoff titer for the two or more Bm antigens.

26. A method for identifying a patient who experiences babesiosis and is likely to benefit from an anti-Bm antibody-based therapy, the method comprising: a. applying a body fluid sample from the subject to a solid support, wherein the solid support comprise two or more Bm antigens comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-24 or 49-54, or one or more antigenic fragments thereof; b. applying an antibody detection reagent to the solid support of (a); and c. identifying the patient as likely to benefit from a composition of claim 10 if the fluid sample from the subject is determined to have an insufficient titer of IgG antibodies that specifically react with two or more Bm antigens of (a) or antigenic fragments thereof, that is, a titer in the fluid sample below a cutoff titer for the two or more Bm antigens.

27. A method of optimizing the administration or therapeutic efficacy of an anti-Bm antibody-based therapy to a subject experiencing babesiosis, the method comprising: a. applying a body fluid sample from the subject to a solid support, wherein the solid support comprise two or more Bm antigens comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-24 or 49-54, or one or more antigenic fragments thereof; b. applying an antibody detection reagent to the solid support of (a); and c. administering to the subject the composition of claim 10 if the sample from the subject is determined to have an insufficient titer of IgG antibodies that specifically react with two or more Bm antigens of (a) or antigenic fragments thereof, that is, a titer below a cutoff titer for the two or more Bm antigens, wherein optionally the method further comprises administering to the subject the composition described herein, wherein the subject has been determined as likely to benefit from an anti-Bm antibody-based therapy or from a modified dose or dosage of anti-Bm antibody-based therapy.

28. The method of claim 26, further comprising administering to the subject the composition described herein, wherein the subject has been determined as likely to benefit from an anti-Bm antibody-based therapy or from a modified dose or dosage of anti-Bm antibody-based therapy.

29. A kit comprising (a) two or more Bm antigens comprising an amino acid sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99%, sequence identity to the amino acid sequence of any one of SEQ ID NOs: 1-24 or 49-54, or one or more antigenic fragments thereof, wherein two or more Bm antigens are immobilized on one or more solid supports; (b) an antibody detection reagent; and (c) a package insert comprising instructions for using the two or more Bm antigens and the antibody detection reagent in accordance with a method described herein, optionally wherein the kit comprises one or more Bm antigen comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 49-54, or one or more antigenic fragments thereof.

30. (canceled)

31. A kit comprising (a) the composition of claim 1 and (b) a package insert comprising instructions for using the composition in accordance with a method described herein.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0127] FIG. 1 is a pair of graphs showing that B cells do not contribute to the resistance of wild-type mice to Babesia microti (B. microti) (left panel) but are critical for resolution of B. microti infection in cd4-deficient mice (right panel). Parasitemia values are reported as mean+SEM. N=5-7 per group.

[0128] FIG. 2 is a series of graphs showing that resolution of B. microti infection in cd4-deficient mice is concomitant with an accumulation of B. microti-specific IgGs in blood. Parasitemia values and B. microti specific antibody titers are reported as mean+SEM. For a given time point, differences in antibody titers were tested for statistical significance using an unpaired Student's t-test (*=P<0.05; **=P<0.01; ***=P<0.001). N=6-7 per group.

[0129] FIG. 3 is a graph showing that activation-induced cytidine deaminase, the enzyme required for antibody class switch and somatic hypermutation, is required for complete resolution of B. microti infection in cd4-deficient mice. Parasitemia values are reported as mean+/−SEM. N=7-8 per group.

[0130] FIG. 4 is a graph showing that Fc receptors, whether activating or inhibitory, are dispensable for resolution of B. microti infection in cd4-deficient mice. Parasitemia values are reported as mean+SEM for 1 of the 4 groups; for clarity, SEM is omitted for 3 of the 4 groups. N=5-7 per group.

[0131] FIG. 5 is a graph showing that the complement component C3 promotes clearance of B. microti organisms at time of peak infection in cd4-deficient mice but does not contribute to the resistance of wild-type mice to B. microti. Parasitemia values are reported as mean+/−SEM. For a given time point, differences in parasitemia values were tested for statistical significance using an unpaired Student's t-test (*=p<0.05; **=p<0.01; ***=P<0.001). N=6-8 per group.

[0132] FIG. 6 is a graph showing the time points at which blood was collected from wild-type mice and cd4-deficient mice infected with B. microti. Specifically, blood samples were obtained at times (arrows) of peak infection (day 18), partial resolution of infection (day 24), and full resolution of infection (day 30) in cd4-deficient mice. Note that on day 24 post-infection, the infection was fully resolved in WT mice. N=6 for the WT group; N=10 for the cd4-/- group.

[0133] FIG. 7A is a heat map of IgG antibody reactivity stratified by mouse strain and time post-infection. Each column of the heat map represents a mouse sample, and each row represents a B. microti protein. Each grey header encompasses several columns and denotes a mouse strain at a given time point. B. microti proteins (n=74) are those significantly reactive to IgG contained in plasma from B. microti-infected wild-type or cd4-deficient mice and are ranked in decreasing order by mean normalized signal intensity for all samples across strains and time points. The grey scale (top-left corner) represents normalized signal intensity on the log.sub.2 scale, i.e., values of 1.0 signify a 2.0-fold increase over background, values of 2.0 signify a 4.0-fold increase over background, values of 3.0 signify an 8.0-fold increase over background, etc.

[0134] FIG. 7B is a Venn diagram showing the numbers of IgG reactive B. microti proteins at times of peak infection (inner circle, n=16), partial resolution of infection (intermediate circle, n=35), and full resolution of infection (outer circle, n=52) in cd4-deficient mice.

[0135] FIG. 8 is a series of graphs showing the IgG repertoire against B. microti antigens in wild-type mice (top panel) and cd4-deficient mice (middle panel). Dashed lines indicate the cutoff for IgG reactivity (2-fold above background). The lower panel depicts strain differences in IgG reactivity. In this panel, dashed lines depict strain differences (gain or loss) in IgG reactivity of 2.0-fold.

[0136] FIG. 9 is a pair of graphs showing the IgG reactivity against B. microti antigens in cd4-deficient mice at time of full resolution of infection (top panel) and time of peak infection (bottom panel). Dashed lines indicate the cutoff for IgG reactivity (2-fold above background). In both panels, B. microti antigens are ranked in decreasing order of IgG reactivity at time of full resolution. Solid grey bars in the bottom panel denote antigens for which the IgG reactivity is above the cutoff defined above. Below each grey bar is reported the rank of the antigen in regard to IgG reactivity at time of full resolution.

[0137] FIG. 10 is a table that lists B. microti antigens for which IgG reactivity is detected at time of peak infection in cd4-deficient mice. Antigens are considered immunoreactive when IgG binding is above that of background by at least 2-fold (1.0 on a log 2 scale). Antigens are identified by their gene ID and are ranked in decreasing order of log 2 IgG reactivity. A brief description of each antigen, when available, is provided. This description includes the Plasmodium falciparum ortholog in the clone PF3D7, when available. The rank of each antigen in regard to IgG reactivity at time of full resolution is reported in the most right column.

[0138] FIG. 11 is a series of graphs showing and comparing the IgG reactivity against B. microti antigens in cd4-deficient mice at times of peak infection (top panel) and partial resolution of infection (middle panel). In the top and middle panels, dashed lines indicate the cutoff for IgG reactivity (2-fold above background). The lower panel depicts differences (e.g., gains and losses) in IgG reactivity from time of peak infection to time of partial resolution. In this panel, the dashed line depicts gains in IgG reactivity of 2-fold. Grey bars denote antigens that gained reactivity from time of peak infection to time of partial resolution. Solid grey bars denote antigens that were already reactive at time of peak infection, whereas hatched grey bars denote antigens that were not reactive at time of peak infection. Below each grey bar is reported the rank of the antigen in regard to IgG reactivity at time of full resolution.

[0139] FIG. 12 is a volcano plot showing gains in log 2 IgG reactivity (from time of peak infection to time of partial resolution) against −log 10 p values. The larger dots depict the 20 antigens for which gains in IgG reactivity reached the highest degree of significance as assessed by use of a paired Student's t-test. The horizontal dashed line indicates the threshold for significance (p=0.05). Numbers denote antigens for which the gain in reactivity was significant and greater than 2-fold (vertical dashed line). Numbers highlighted by a circle denote antigens that were already reactive at time of peak infection, whereas numbers highlighted by a hexagon denote antigens that were not reactive at time of peak infection. Each number corresponds to the rank of the antigen in regard to IgG reactivity at time of full resolution.

[0140] FIG. 13 is a table that lists B. microti antigens for which IgG reactivity increased by more than 2-fold from time of peak infection to time of partial resolution in cd4-deficient mice. Antigens are identified by their gene ID and ranked in decreasing order of the gain in log 2 IgG reactivity. A brief description of each antigen, when available, is provided. This description includes the Plasmodium falciparum ortholog in the clone PF3D7, when available. The rank of each antigen in regard to IgG reactivity at time of full resolution is reported in the most right column. Antigens denoted in grey were already reactive at time of peak infection, whereas antigens denoted in black were not reactive at time of peak infection.

[0141] FIG. 14 is a series of graphs showing and comparing the IgG reactivity against B. microti antigens in cd4-deficient mice at times of partial infection (top panel) and full resolution of infection (middle panel). In the top and middle panels, dashed lines indicate the cutoff for IgG reactivity (2-fold above background). The lower panel depicts differences (e.g., gains and losses) in IgG reactivity from time of partial resolution to time of full resolution. In this panel, the dashed line depicts gains in IgG reactivity of 2-fold. Grey columns denote antigens that gained reactivity from time of partial resolution to time of full resolution. Solid grey columns denote antigens that were already reactive at time of peak infection, whereas hatched grey columns denote antigens that were not reactive at time of peak infection but gained reactivity from time of peak infection to time of partial resolution. The dotted grey column denotes the single antigen that was not reactive at time of peak infection, did not gain reactivity from time of peak infection to time of partial resolution but gained reactivity from time of partial resolution to time of full resolution. Below each grey bar is reported the rank of the antigen in regard to IgG reactivity at time of full resolution.

[0142] FIG. 15 is a volcano plot showing gains in log 2 IgG reactivity (from time of partial resolution to time of full resolution) against −log 10 p values. The larger dots depict the 20 antigens for which gains in IgG reactivity reached the highest degree of significance as assessed by use of a paired Student's t-test. The horizontal dashed line indicates the threshold for significance (p=0.05). Numbers denote antigens for which the gain in reactivity was significant and greater than 2-fold (vertical dashed line). Numbers highlighted by a circle denote antigens that were already reactive at time of peak infection, whereas numbers highlighted by a hexagon denote antigens that were not reactive at time of peak infection but gained reactivity from time of peak infection to time of partial resolution. The number highlighted by a rectangle denotes the single antigen that was not reactive at time of peak infection, did not gain reactivity from time of peak infection to time of partial resolution but gained reactivity from time of partial resolution to time of full resolution. Each number corresponds to the rank of the antigen in regard to IgG reactivity at time of full resolution.

[0143] FIG. 16 is a table that lists B. microti antigens for which IgG reactivity increased by more than 2-fold from time of partial resolution to time of full resolution in cd4-deficient mice. Antigens are identified by their gene ID and ranked in decreasing order of the gain in log 2 IgG reactivity. A brief description of each antigen, when available, is provided. This description includes the Plasmodium falciparum ortholog in the clone PF3D7, when available. The rank of each antigen in regard to IgG reactivity at time of full resolution is reported in the most right column. Antigens denoted in grey were reactive at time of peak infection and/or gained reactivity from time of peak infection to time of partial resolution. The antigen denoted in black was not reactive at time of peak infection, did not gain reactivity from time of peak infection to time of partial resolution but gained reactivity from time of partial resolution to time of full resolution.

[0144] FIG. 17 is a series of graphs showing the inverse relationship between parasitemia and IgG reactivity against each of two B. microti antigens at time of peak infection in cd4-deficient mice. These 2 antigens, namely BMR1_01G03280 and BMR1_01G00985, ranked first and tenth when considering their IgG reactivity at time of full resolution in cd4-deficient mice (top panel).

[0145] FIG. 18 is a series of graphs showing the relationship between parasitemia and IgG reactivity against each of four B. microti antigens at time of partial resolution in cd4-deficient mice. Three antigens, namely BMR1_01G03280, BMR1_04G05532, and BMR1_04G07360, had IgG titers at time of partial resolution which were inversely correlated with parasitemia at time of partial resolution (left bottom panels). A fourth antigen, namely BMR1_01G02100, had IgG titers at time of partial resolution which were positively correlated with parasitemia at time of partial resolution (most right bottom panel). Note that BMR1_01G03280 and BMR1_04G07360 were already reactive at time of peak infection (solid grey) whereas BMR1_04G05532 and BMR1_01G02100 were not reactive at time of peak infection but gained reactivity from time peak of infection to time of partial resolution (hatched grey).

[0146] FIG. 19 is a schematic that classifies the 24 B. microti antigens which displayed IgG reactivity during the resolution of B. microti infection in cd4-deficient mice. Sixteen antigens were identified as IgG reactive at time of peak infection. Of the antigens identified as gaining IgG reactivity from time of peak infection to time of partial resolution, only 7 were not reactive at time of peak infection. Of the antigens identified as gaining IgG reactivity from time of partial resolution to time of full resolution, only 1 antigen was not reactive at time of peak infection or had not gained reactivity by time of partial resolution. Among these 24 distinct antigens, 15 are predicted to lack a signal peptide and are referred to as “group #3 antigens.” Of the 9 antigens predicted to contain a signal peptide, only 3 had an IgG reactivity which was inversely correlated with parasitemia at time of peak infection or time of partial resolution. These 3 antigens are referred to as “group #1 antigens.” The other 6 antigens are referred to as group #2 antigens as they are predicted to contain a signal peptide but displayed IgG reactivity at time of peak infection or partial resolution which was not inversely correlated with parasitemia measured at the respective time point.

[0147] FIG. 20 is a table that lists the 24 B. microti antigens identified as displaying or gaining IgG reactivity during the resolution of B. microti infection in cd4-deficient mice. Antigens are identified by their gene ID. A brief description of each antigen, when available, is provided. This description includes the Plasmodium falciparum ortholog in the clone PF3D7, when available. Antigens are classified into three groups using two criteria, namely the predicted presence of a signal peptide, and an inverse relationship between IgG reactivity and parasitemia at time of peak infection and/or partial resolution of infection. Within each group, antigens are ranked in decreasing order of their highest IgG reactivity or gain in IgG reactivity (grey boxes). For the purpose of this application, a sequence ID number (SEQ ID NO) is attributed to each of the 24 antigens.

[0148] FIG. 21 is a graph showing that in the absence of interferon-gamma activity, resolution of B. microti infection requires B cells. The solid triangles indicated in the upper portion of the graph correspond to ifngr1-/-+18B12, while the solid triangles indicated in the lower portion of the graph correspond to B6.

[0149] FIG. 22 is a graph showing an experimental design to probe the humoral response in ifngr1-deficient mice. The d22 indicator is plasma obtained from wild-type (wt) mice, while the d0, d16, d24, and d35 indicators are for plasma obtained from ifngr1-deficient mice.

[0150] FIG. 23 is a series of graphs showing that lack of interferon-gamma activity alters the range of cognate antigens recognized by IgG antibodies.

[0151] FIG. 24 is a series of graphs showing accrual of IgG reactivity during resolution of B. microti infection in ifngr1-deficient mice.

[0152] FIG. 25 is a series of graphs showing an inverse relationship between IgG titers and parasitemia at the time of mid-resolution.

[0153] FIG. 26 is a table that lists 18 B. microti antigens identified by a screen of ifngr1-deficient mice.

DETAILED DESCRIPTION OF THE INVENTION

[0154] The invention is based, in part, on the findings that a) resolution of B. microti infection in cd4-deficient mice requires antibody-producing B cells and antibody class switching, b) such resolution is concomitant with the accumulation of B. microti-specific IgG antibodies in blood, and c) these IgG antibodies target a restricted set of B. microti polypeptides. The invention is further based on studies in a mouse model of interferon gamma receptor type 1 (ifngr1) deficiency.

[0155] Accordingly, the invention provides compositions for use in methods for the prophylaxis of babesiosis, the monitoring of prophylaxis efficacy, the treatment of babesiosis, and the monitoring of treatment regimens in a subject (e.g., a mammalian subject, such as a human), as well as such methods. The invention also provides kits that can be used to carry out the methods of the invention. The compositions, methods, and kits of the invention are described further, as follows.

Compositions

[0156] In general, the present invention provides compositions comprising one or more B. microti (Bm) antigens for use in methods for the prophylaxis of babesiosis, the monitoring of prophylaxis efficacy, and the monitoring of treatment regimens for babesiosis that comprise one or more anti-Bm antibodies. The present invention also provides compositions comprising one or more nucleic acid molecules (e.g., RNA or DNA) encoding one or more Bm antigens for use in methods for the prophylaxis of babesiosis. The present invention further provides compositions comprising one or more anti-Bm antibodies for use in methods for the prophylaxis and the treatment of babesiosis.

[0157] These compositions and methods can be used to generate or provide immunity to B. microti and thereby to confer partial, enhanced, or full protection in humans and other mammalian subjects who are at risk of exposure to Bm and at risk of developing babesiosis (e.g., mild or severe babesiosis, including persistent or relapsing babesiosis). In various examples, the compositions are useful to (a) reduce the chance of a subject to become ill when infected with Bm, (b) reduce the severity and/or duration of illness in an infected subject, (c) reduce the parasite burden in an infected subject, and/or (d) reduce the chance of dying from babesiosis. In various examples, the compositions are vaccines.

[0158] Babesia Microti Antigen-Based Compositions

[0159] Compositions of the invention, which can be used, e.g., in the methods and kits described herein, include one or more Bm antigens and optionally a pharmaceutically acceptable adjuvant, carrier or diluent.

[0160] Exemplary Bm antigens for use in the compositions of the invention include BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID

[0161] NO: 7), BMR1_04G06070 (SEQ ID NO: 8), BMR1_04G09385 (SEQ ID NO: 9), BMR1_03G04485 (SEQ ID NO: 10), BMR1_03G01645 (SEQ ID NO: 11), BMR1_03G01960 (SEQ ID NO: 12), BMR1_04G05080 (SEQ ID NO: 13), BMR1_03G00820 (SEQ ID NO: 14), BMR1_01G02100 (SEQ ID NO: 15), BMR1_04G07360 (SEQ ID NO: 16), BMR1_02G02185 (SEQ ID NO: 17), BMR1_04G08260 (SEQ ID NO: 18), BMR1_03G02345 (SEQ ID NO: 19), BMR1_02G02960 (SEQ ID NO: 20), BMR1_01G02545 (SEQ ID NO:

[0162] 21), BMR1_03G04110 (SEQ ID NO: 22), BMR1_02G02560 (SEQ ID NO: 23), BMR1_04G05635 (SEQ ID NO: 24), BMR1_02G01795 (SEQ ID NO: 49), BMR1_04G07915_s2 (SEQ ID NO: 50), BMR1_01G01620 (SEQ ID NO: 51), BMR1_04G05940 (SEQ ID NO: 52), BMR1_02G02565 (SEQ ID NO: 53), and BMR1_04G06705 (SEQ ID NO: 54). The amino acid sequences for the 24 full-length antigens or their ectodomains are provided in Table 1.

TABLE-US-00001 TABLE 1 Amino acid sequences of exemplary  full-length B. microti antigens or their ectodomain SEQ ID NO. Amino Acid Sequence Gene ID  1 DVYEISSGNPPDIEPTSTSLETNVVTNYIPEPNADSESVHVEIQEHDNINPQDACDSE BMR1_01G03280 PLEQMDSDTRVLPESLDEGVPHQFSRLGHHSDMASDINDEEPSFKIGENDIIQPPW ectodomain EDTAPYHSIDDEELDNLMRLTAQETSDDHEEGNGKLNTNKSEKTERKSHDTQTPQ EIYEELDNLLRLTAQEIYEERKEGHGKPNTNKSEKAERKSHDTQTTQEICEECEEGHD KINKNKSGNAGIKSYDTQTPQETSDAHEEGHDEINTNKSEKAERKSHDTQTTQEIC EECEEGHDKINKNKSGNAGIKSYDTQTPQETSDAHEEEHGNLNKNKSGKAGIKSH NTQTPLKKKDFCKEGCHGCNNKPEDNERDPSSPDDDGGCECGMTNHFVFDYKTT LLLKSLKTET  2 IITDGLSAIGSVASEVGNTVKDVSSEALLGELQQIADGGKIIRDGTESNFVNSIANTV BMR1_04G05532 MKNVVGTAVLKASSGITHNGDFAFYNFMYPENDDYPWACICDESDYEEYIKGKKD ectodomain KVRCRNYIDSSLQNAVLYCNPANHNSSINDNANNNPPKQIDNHVSIPQTAPANHT TVLSTEVDTNHNEQKQPNSPSVPSESQNSVSAPKDESVSSTVEGAKSSS  3 TLVSKITTPNNLPGIDTCSNWEDVSVCTTKNTRNCISGEGKPKDCFAIGKSLFKTFPN BMR1_01G00985 CYEGVIIDQVTFSGFETLEIHYCDIDKILHKANEVVKSIHELKEKTNQLTEKIKDIPDLID ectodomain KVIKVNSEISKIFHQDKIKHMEKEANDFKNALKTTRNYIISYDSLDKTKQSNLLTSLGK LMNKIKTKLSEMDKTLHSTLDTNNTIIDLVNNNSSHVKHPNDFNKTMELYNETITK ADAIKKNIEKLKEHRKISTHKTIFSNNIDKLIDNLTDYFENINRSIDAVRDKLSKYQLET GKMVLLFKNVNEIQKHIKNTDMHIRTCNYDFSDIEQKYSLITAKITVEDGQSITTSNK STVDIPEEKVDRVNVNVDKAENSDNETSQENTSVKPTDHKEIEDSASEENAIGENG DYDSDEDIDTNDVKEDHENAIDSEYTVSSTGDVLEDEVVEENAIGENGDYDSDEDI DTNDVKEDHENAIDSEYTVSSTGDVLEDEVVEENAIGENGDYDSDEDIDTNDVKED HENAIDSEYTVSSTGDVLEDEVVEENAIGENGDYDSDEDIDTNDVKEDHENAIDSE YTVSSTGDVLEDEVVEENAIGENGDYDSDEDIDTNDVKEDHENAIDSEYLVSSTGD VLEDEWEENAIGENGDYDSDEDIDTNDVKEDHEDAIDSEYLVSLTGDVLEDEVVEE NAIGENGDHDSDEDIDIEEVNEEDHEDAIDSDNSISNSENVDTTPTENVDTIPTKNA NTTPTKNANATPTKNVDTIPTKNVDTIPTKNANTTPTKNVVTTPTKNANTTPTKNV VTTPTKNANTTPTKNVVTTPTKNANTTPTKNVVTTSTGNVRTKHTSTNSHVLAPDT DEYPAQISQHKTIDKYYQSLELEDEENADISSSDKPVSPINLEDKNSTYDHMHKTDN VKSAGIASYD  4 NRSCPGNNGVGGGSGDNNSGIIPNDPHPCCNNLRQKPQYQTKPENELVNDDRDL BMR1_02G01760 NFNKIRGGKQIITFTVPSIDDLKNKRLSDSEFILSEKANPLISSGDSKNVIVFEVKNDNE ectodomain KLMGSVEVGQWEVTITTSCIRRIVIFDSNEVSDNIPMYIYIVDYFEGGNSTVSKFFFA NNRWNDFTNHTPNAA  5 FLLNRSEFKWFKVGLIITTIFPFKHSFDYNLTHIFLFSICTLIFCVKPVDEESGAKKEGFD BMR1_03G00365 FKKMVPDKFKKYT ectodomain  6 DSGNSSPQTPPETSSPINGVIGDENNGLEHLSSSGLEVDDNLPELLKTSPFSGQNSD BMR1_03G04695 VQSASTPVEPTTPVHSNDQSNPITNKVDTNSNDHTDIKNEGSSHRTSSNNSSVTTN ectodomain TNNEIRNGGGPLDQNEDKAEDEGETDAEGRGWNERTKNKPTFNATNRDFVDDN LPELLKTSPFSGQNSDVQSASTPVEPTTPVHSNDQSNPITNKVDTNSNDHTDIKNE GSSHRTSSNNSSVTTNTNNEIRNGGGPLDQNEDKAEDEGETDAEGRGWNERTKN KPTFNATNRASPDGIGKMNMEEKQLENFINVSSNALELDISIGRDNFATKFLAQHV NIFGDRISGLSAAYVEGYNNLAKIMYNSHSVLFDRKFNGAVISDNLIGNIADFGSYFL EISPNTTRTNRSDYLKSVVLSKVQYLLSADFSTTDNIQRLTNLALALGYNNVKENNP GNSQHSITTSLSTELFWSFGNNIFLFGHLATLMLAYLESNAYFTSGATRPFFSWQTL VSTGGNEKFDKLDSMCGVIRGSKYSRKNNGFIKPHYKRLRRKTLLEGEPRLLCSMLE EALDTVDKAIKFKGEELNSQGANIENSVSNDINSKRLQAKLCSNLNDSLINVSCDFRS SKLDKHNKKLREAFDLLLACGNLNTGKKEAFPEYLRLISNPFEYGDIFSMTMWWDP REFDGKQGWVEIYKKLRKNIMKPELKNVDMQLKYDSAISYYKQLKESETYPKKNIP WARLYLYMSVIMSRSNAMSWAEDALRSFSNLYRMKPSLVMRGEGLETLLNYCAP DPVALSHIFLYHFLTKKDAGKDLEKDLRRLEKGTLLSRIVNSSSIFIPNKLKKFLKMGA RGFFNKKLNTLRAKSTLLRLFPKNLLHSALGAIEFTTHSLATLQISKNMDMWESLAQ TKNLDAGGFPGEIDSLFNHWSESGGYSGYITGKLENGDDLTGDDIKKMNIKAPINN DSLNWQKYINKKISEHFGKFLNLPFIQASGSQKNYIYQLVRDSKANLDDNLEQTVFF GKVLPPGKTNNVIKKLKRIADSFTSMLLRSSARPVDHAVWVGVKINVPIVIHITKKLY MIQRDMPRKEAWNLESAFLDLLQDLVIMVTNPGKRSPIGFETIGGNPGLPEISIRYP HMSIEERKIEFQHSQCADHCISIWRSLIAFTLNTLNNPAAIKQFEKSLSSNSSLNDMS KPEYINSFKYILKGDSVLHMYDNMLPRKVKREIKALKYGK  7 LPDILSQNNTFKSFLEVNNVDQEDLICNKALCKSTDSINRNTSSYCYKYKLCSKCSVS BMR1_03G03430 NVPDHPVCYLLDNDHNYIHLMEGHLGSQPIGSANSHDNSSHDEHSSHSNNGDM ectodomain MDEHEEENFLQEYESKSMKFIPTSNMSDFDHARRSCAVDSKGNVMISVRLIIQWY MSKDKSNNQQHHGNDDDSQNYDANYLQLTPMYSDDSVNSSMLEMDHDDSESS NSHKSRMANMAKNFQVLKNIHKSAVKRYKSPKAKIYLIFSNPKINSCRHPVIYNGKI SPSSMFVAKLESTISQIDLTQDLIKSSIETIVSCEACDKLKYNSCIQVTCAKNTPGAASL AMGSAVYVPMTNTTIGVNAHNPNAVVAAGIPMGKIPVIPHPAAISGGNVGHLNN GLHKAVNNAVMMPNGTSLPVQSGVVIKSLYNCLAFLLTILYLNF  8 NPIFASATSAPSRNRAQDMTKAECIELLKGIVKSQEETKIVMKKLTSDLINNPLRLEQ BMR1_04G06070 VYTKASQMQPEDPMEQWGVTVIDLDHLIEKYQHDPIVKDYILKIMNSPGINDTTLS ectodomain DDVRNITISQILAIHEYMLSELESVVREFKSLQNRQTMEIKTLTIAAQAIVAAKVEEKF NLTSDQVESAVIINHAELTASHAFTRLTMQMQTEMSELIGCQFPGW  9 STNGKGGVDSVSKKSFVIELEDSTFERKTQASSGGTSGVWFVKFYAPWCGHCRSM BMR1_04G09385 ENDWNELANILGKQINVAKIDATKHSVTAKRFGITSFPTLLLLKDGNFYQYENNNRT ectodomain ADALKQFALHGYKQVKSKPVPKEWSYFVRFKFFIKSGFYEVKRIYQLAYPGFIT 10 MAKLHESTSSASASFDPEKSDYDDTYVLTETTPTYIRHGFVRKVFAILFAQLLVTLGFSL BMR1_03G04485 ICYFYRESVHSFISKNIWIFPTLAILSFITSLILIFSPSLSRRYPLNYAILVIETLYFSFIVGL full sequence SCAFTKSPTAIVLSVSITLGIILLVVLFTLQTKIDFTRYIIYFILFSFVTLVFGFIGIFVPFDT PLRMFYYGLGVLGYSLWMVLDLQLIIGGKTYEWTVDDYVPASLSLYTDVIGIFLNVH GMFSDR 11 MTITLNIKVNSETNFTVEAEPSFTVKELKILCESQSNIEAQNQRLICKGKLLKDTDILSD BMR1_03G01645 VGAVDGATVYLVRSQVNKTQSAAPKQNTVPQPTLQTTNQPAGQTQTSGLGFQQ full sequence QGFQQGFSGSQQPGFQANPFQSMLAGGFPNLDPTQMMEILNSPMAQEAMQR LSQNPEVLRNILQNSSLMTPMLEQNPMLSEMLSNPELMRSMLRPEVLQAGLQM HQAMQQQQQQQPGTQTNPIGSQNPDFSNMMRQMMNVFQQNPSVAQPTAP QVYTDPRPPAERFATQLQALAEMGFIDTEKNITALIATNGDLNATVTRLLESNF 12 MEEAERKFKEFNWADSQGWRIYWDNLYPTPPLSKVDKFKRSWFKRNVDSNISST BMR1_03G01960 PLSEVGKQTQQTTPNQYRSQGNFAILTLEAGVRLLYLLITAPLFVLPLIGVRLSRYIYY full sequence HYYIDIALLLIFLLSGIVRERGLPKMDSVWLASAFYSDMTQYIMYTCILMMSAPRPV YLILPFLTCLIGLNSLAETNLSKLPKWLENIVGEIFKYTKDNIYWLMQTRGDVECYLLF YIVFGFLTKSSAVITLMAYINFMKLRIGIGDPFIMSAFSKLHGCIVKLLSYDMFGHIPL RMYLKISELLTKYMSGPRPQY 13 MEDQNTTNESISNLHMENYFPKDIFSNLDNQKNLKTYHSKTFEKYFESAAKDNVER BMR1_04G05080 CRTSAVKEWLNRNLPSEYNERHKPTLKLNLSPNHLNSTYNKQISDYTRNAYNRIEQL full sequence KKLQEAYSLLRQKLQEKRRASCHKEVSEAEASVLNTQRLIISLKREDKDKIATELLIQN AEELGIPSKDLETLNGYTFNEALKTIIDIISNMINNKFMTNLKDRCESARRKAGSEYR DEMERIKVDLDMYKTKSEKLESTISTLNSYADSSKQNAEKVMELQHSLEDSNRQIN QLKDSLYNMAKVNEELEKNEVKLEESLVELERYKLESQKLESVIKDLELLNQQKHDN EELIKMLHDELDQCKSKSLQLNKKIEDLENSNKENLIPLNNELAQAYQKLSELEHSYE QIEHQKNEADKKLESSIDEIEKQKQHSEELEQSITKLKQTIEEMEKETTDQVNDLQTC LIDANCKIESLEGTISQLKQLNLELEGGEHRIQELQSKLTESNSTIEKLEKTITELENVSS KYIDYDEKMDNLQKQLKEYTEKITVLENNASEFNYKDQAETLKTELDKSQLKIMELE TMIKENSEKTERVPSPRKDNEEVDRLTSEILQLKNQVDILQNEKTDLEQKLSQQSPR KDNEEVDRLTSEILQLKNQVDILQNEKTDLEQKLSQQSPRKDNEEVDRLTSEILQLK NQVDILQNEKTDLEQKLSQQSPRKDNEEVDRLTSEILQLKNQVDILQNEKTDLEQKL SQQSPRKDNEEVDRLTSEILQLKNQVDILQNEKTDLEQKLSQISAVIEENRQYKEKIE LLERKLNEINKEKPKDSFTNVEVINAAFEDVRSLPINSSNASDWTAMPSELELEEHKL YKKKSSRKGKKKSSREKETSRSDISSRSTSRHSKKDKPTIVDNNSTDVEASDSNEQMI SDPVESITDQLNLVKQSTIQLTELGYDSISNVGSYLSDYIFGGN 14 MDDLPGSLHQSTPNEKPMAPPTAPKSAPHVPISVESKELSKEIPKESPMTKEDKKD BMR1_03G00820 VAKSKVSAAVTEKKVVKEPVVPKITIEMKKFSMSRESTQYSIFIIFNLIFALLYIFKVRL full sequence MAIFCNLIIVAISIGAILSSIDPNRRKVDETNVNIIFISPTTVSDLAIVITAKLNQYISYFR RILLWQDFILSTRFTLCVYIMGILFKIIPLVALIYIMCWAFYLYMFICKEMADQLLDIIM VYLKRVSGNFDEFCCNIPKMKDVGKEL 15 MFNENEIPQFQRPFTPSKDTEIDTSINFPANSILNNISFQKLLDWLDECTEGLPIVESF BMR1_01G02100 ARRFNVTRGHIAAIFSAILILYFIFGWKINIFCNTIGLVYPAFKSHKVLLIHRAMTESPK full sequence ATATITTGGKDKENDTNPQMPTCLNGIQGEIMFWLRYWIVYSLYLFISILIFPLISWL PLISIVRVGFILYLYHPYTRGANAIYYLVISPLLSKNQKIIEQAIDTLERVAMGEIRKFTE KQMKLH 16 MDSIEECNKLVDAVTKLATSFDYQAQEYLYNLTRDENAINIALSFLLSNKYVLNYSSS BMR1_04G07360 YSNEILQYITDVRGPSSCCIWDNIQLDENTSRHLGHITSILFKEHMHIVLCFDDAKLIA full sequence LIDTLVTIWQLQSTISLVTQSCFADNATDDHITRVISMIIFKKPQLLTHFINILNTPEVT DKYVADFSMKFKLRNCDRDDIYVTRYRHMIVYVLAQVLENFVSSNVTDKISFLPINF SDLVILSGNCNNRYLYSCALLIVNSLNFHISEELLHQLLVIVEKSGFDCDILEMWNFAI SHLQYLKVDNFMMKSFRLVQNGLIESTNPINIVPVLNGITVYYVNNSSVPTEIVRAY RQLLSVESLDIPIEIGELFAAVRNACTESLITYDKIASFVSQFDIRMISSRLIELCNPNM QCWSWLNVNCCVEEFPTDYDIYIDSMKNVFKDLFFILPEQLLDTIISEILQSVNENTE TSLIALICYDCLEVRHALAILDKIKSLFTLKLSSNYDFILTCMFCQSIFVPHLHRIKDILFQ RFVINMKISNIWSKRLAKCIAILNDRDSVHSVIECVQYILETSKSKGVLSQNHYPSILSL SNLLDTLPQMPCDVNLTGSNYIFCKCLLALSISTRQLSQILPKIALNLDILYEGDVDND LFCLSTSDSQAAVNLLMQLYIQNKVTDIPNELHEIRHPGLLMLCNLNENFEQFRMN KCVEFMSTVSQESCCHCAWACIAYASYVIEQKFNFEFSMEMVKVIYRVLPCLIKMV KSKNEPLHWDLDAILEYRINEIHPSIKCLKGTIWNIYYDGTVSVGSDACKYLSLVNKY APRIIKSLSNPNVLQLVYQISMCTGSIEVIANKIAISL 17 MSCILKCNNEDELVVDGEKPKVVEYVEKPSVIYKPTTVVPPNSLIEITAPKDLPQNPT BMR1_02G02185 FFPTIDTFFDNDVKQIVLLMELPGFVAGDIDLEVGEGEVCVCGPRSKEELYEKYGQN full sequence LDIHIRERKVGYFYRRFKLPHNALDNTVKASYQNGILEVRITCTEFSPKTRVEITS 18 MNGSVEELLNRLSAINDRCYLLVDEIKNYMSNKLYHELTLALIELFTMSEISCNDRLLL BMR1_04G08260 FEMIVHPIKNDLNILKFSHILRLSSEHLEPLASLDQLSKYDNYLSTDTQASFIKIAKSYH full sequence HTRNQSYDQSLKLLEEVKPEIESGFGLDITVISAYYKVSANLNKATHKYNSWYQDSL MYLNYTPLDSISPTERDELALDIAIASIAAPDNYNFGAVLIQPLINTCLKQHSTFGWV YAILMALNDGDFTQYDEIISKYKVQISHSELNHHKEQLQRKITLMAFLKLVFRKAKK QRIFTFEEISQNCRIPIDEVEYLLLKAMCNNVVKGKINQVEQIVSFTWVQPRIIDSTKL TVLLDGVNEWNQQLKALINKLKEITPELLVS 19 MSGLFGQSQQIGGGLFGQSNQQSGGGLFGSTSQQPTQTCSGLFGSSPAPANSSIF BMR1_03G02345 GSNTQSAASSGGIFGSSTAPVNSGGGIFGQSNTNVSSGSGLFGGGNTTGQSGGGI full sequence FGSSTTSAPASGGGLFGQTGTTTSGGGGLFTSSFAPAPSSGGLFGQPSTPATSGTGL FSSTSTTQPSSGAGLFGSSTTPASGSGGLFGQPSTSTTTSGGIFGSSTTSAPASGGGL FGQTGTPASGSSGIFGSTNTTTSASGTGLFGSTSTTPQPGSGSGLFGGGNTTGQSG GGIFGSSTTSAPASGGGLFGQTGTTTSGGNLFGTTSTTTPAPASGGLFGSSSTTSTT TPTQATTTVGGGGLFGTASATTAPASGGLFGTTSTTTPAPASGGLFGSSSTTSTTPT QATTTVGGGGLFGTASATTAPVSGGLFGTTSTTTPAPANNTTPANTTTVPTAILTTS TPSPATDGLFGSTDVTTTTDSTTKLVGTSPFEKQTDSGPDVTAATNDTPNAFITDKP TAGGDLKGQVELSFSSVEHECVQDLLSNWEKRMEVKIQRFTEFAQDIQRIDRDLIL QTEKLQVLLDEQATVQERQNQVQEMIQVIEKEQQQVLESLDIMDTALETLLGPDK KITSKSGETIDFVSNKLRDLEAQLKAAHDVVDSVVKASQPEPLANVAKVFAFHQDTI ENIQLQTSEIEKKLDAIKQQQAV 20 MASLLKVSPQDNIEFPLVLYTPLNANLLLENLSGVHVAFKIKTTAPKGYLVRPSTGTI BMR1_02G02960 KPGEALTVQIILQPLSEVPNVVNDRFLVQCTAIANDELVSKDFWTTLDKASIQDHRL full sequence NVTFKKDIGLNIQTSQSNIGVPPHIAARILTPLGPNAGVAELRQKYEELVSYCLTAEK QKAALVKDNEKLRQRLHLGPNDPASGNKWPLEGWHLPVMVIILVIILKAIGYW 21 MSQGPAIGIDLGTTYSCVGVWKNETVEIIANDQGNRTTPSYVAFTDVERLVGDAA BMR1_01G02545 KNQDARNPENTVFDAKRLIGRKINDPCIQSDIKHWPFTVAAGPNDKPVIKVQFQG full sequence ETKSFHPEEISSMVLTKMKEIAESYLGKTISNAVITVPAYFNDSQRQATKDAGTIAGL NVMRIINEPTAAAIAYGMDKKGTSEKNVLIFDLGGGTFDVSILTIEDGIFEVKATQG DTHLGGEDFDNRLVNFCVDDFKRKNGGKNISTNRRALRRLRTQCERAKRTLSHST QATIVVEAIFDGIDYSCNITRARFEELCAEMFKNTLIPVEKALADADMDKKQIHEVV LVGGSTRIPKIQQLIKDFFNGKEPCKSINPDEAVAYGAAVQAAILTGEQSSKVQDLLL LDVTPLSLGLETAGGVMTVLIPRNTTIPAKKEQEFTTNENNQTGVMIQVFEGERSM TCDNNLLGKFHLTGIPPAPRGVPQIKVTFDIDANGILTVSAADKSTGKTEHVTITND KGRLSQQDIDRMVAEAEKFREDDEKKKRCVESKNELENYCYSMKNALEEEGVKSKL SSSELSEAQKLLQNTFSWIESNQLAEKEEFEAKLKEVQAVCTPLTAKLYQAGGGVPG GAAPGGFNAGGAAPSGPTVEEVD 22 MKLIACTLKNVETCVEVDPSDTVDALTNKIGSSLNNASASKMRLIHAGKILKMEQKI BMR1_03G04110 SDYSDIKDGDKIIVLFSKQSEASTIANPTPAPTSTPIADANTSPPKPIPTTDPNALLMG full sequence EELEKAINGIVEMGFDVESVKAAMSAAFNNPNRAIELLTRHEVDVSDHDTHQSVQ TTGVLDELRQHPMFEQMRAIVRSNPQTLPQILSLIGQSDPSLLQAITENQEEFIQLLS EPVLGTSGDFIDAQSITLTPEEMESINRLEGLGFSRPAAVEAFLACDKNEEMAANYL LENIADYVSDNDN 23 MDGQTEQQLIEENIERFRILYQLHLDNNEPSPTAQFNYACALVCSNQRSHNDTAIY BMR1_02G02560 LLDELVRIRYESEECFYQLALAHMKRRSFVKSKEYLDRIIALEGSNQRVMALKSVVVS full sequence LLAQDTFMGGLLGATAAFAIILFFTMKRNT 24 MNQNSLCCSKGFTMFAGGAFFLVSFKPETVITNPLLLRPLLNVSWGYIFGSHLWAA BMR1_04G05635 ISTYNKKYWENRIIPDYANSPSREIMQSRLKINESRIYRIYLENLIQTNVLANGILLVTT full sequence SALAPSNKFLRICSGAALLLSIGNVVFALPEDEKDDDVGVVKTSSTSCFLSEVLSFCTF GAIVPYVFA 49 RNPRHTKFHKKHTPITDISPTANNLDDYELITYGNDEGLHDEPGLGSIVTDIEIRTPA BMR1_02G01795 NFDGTAGNKGRKSKRTDKPVKKAKPVKTRNPVNITEINNANDEDTIDADLDEDLED ectodomain DTYTDKPTGFFM 50 SIDSQKSDNDVANTSETSEKLNYYDARDDFLHTMDMVNLVGGSCTLIDKANQPSD BMR1_04G07915 FKQLLNASIFGYGRISALLTQTKSIYDVTVASTLAAVFGKLMQINLDDEGLAVEQWS ectodomain ARVCSMLEIAEASLLSTSFKILADRLTKHCGRIAEVFLSQKENDPIDKNKSSDSINDYS SGEGVDVVWSVSTECLMEFIAPNSPGGFTSKWTFVTFKHLLMQLSISIIMCEYQLR DPKLLDDEIEGVENLLFRSWDVLEHYSNIQFYTQLDGASGIMTFAQSNLMPLVKRD GDKINVSWNLQNEFEADPSSNSSGDLGLAAGDNASSDGEKPVATDPPFYSRRPRT YSMLSDYKRRLSLTYEMSDEDTPDEDDDFEREDEEVIVEKETESTPNKQIKNAKNVF GRRKTPQNKVFRPKLYPHDTVSTSSVTYAIKTNNENQIQFKSGAAQPIDSDIDSVPR AKASNPSIDSGNDSVPRAKASNPSIDSGNDSVPRAKASNPSNGSDIDSVPRAKASN PSNGPGNDSVPRAQASNPSNGPGNDSVPRAKASKPSNGSDIDSVPTAPASKPSN GSDIDSVPTAPASTSKSVRGTTGTGSNSKWSSVRNSVLKNKTEENDNNEGPSKASG SAGGGLKGEISFSDTVSILRFRSEPLRWTENTKVEANMHRKMVNKCQVEQLRPLSI DYYNKISPPNLGHPVMGRATASSSSTLLPKFMGIGAKVSKTSNNPSMDTLSNFWG MQRHDKELSGIRKLDKTVSQMAILDRFSRLADTCWDVASGRPSGYISPETMYRLG GNRKDDYIHHVTRVYPFNLVKAYRFLVTKEEPQVQSNGDDNFEFSLFLQAPEFVSIL PNGDRAEALVIEQKLVSTIRTLNTNSTEDPPISVCGYVYKRNDVDRVLIGEFGVKLPS TILEHVYKIHTPYTILIHAKFTDSKFNKLKAVMQFLQGTHFGDFTLKFVYKGMVPSK NVVKDSCHECLIGHY 51 MDNEFTDFSLDKFGTTEYYINNHNHNSNDTVEDPFYLTHNHDSNDNVKPSILNPA BMR1_01G01620 NASSCIPASYWQQQMEYNDSHLDNSRSSMMNENLIIKELGVDDSPQNDNEITSID full sequence DITKLTEGELTTHTHEPYNLNYDSKTDLQNAFDTFYHDFSLFTPTETLPESQPCTIDSS GHLFNHKFDISNNDSYYQSNEYLNTLPQSFGHWTRTSQTNNCSMEDKHRDDDN NKLSTQLSTFLNPINSDNVDNSGHLYLDINASNTMATEYMHSNQPSGKPFDPLTLL NRVKLRDSTAQIALAQIFNEAQEQKQTLNNVLDSLFDNVGYEGNLLEGDFKFPFISD SLLTATISYSVRTANDEILSILVCYAITNKVNLRADLVADIIDIFFKSLRYSDAYKLIDYCY NDKTKLDSILKTDNFQHMFNMCKEITVDNKISFEIYQYLLQCNGEKEILCKIVESIDE AIDSDSHLASLLRTSSIPFIIRLFVERGDLNKLSYYLKIYLSKPSPSTHDLVEIIDVILETNR AQLQSVVQQISESNSFDLTILLYIFTFLHLKNKSNIIHMIYADAIDKQIQNIPSDLKAVL TSLSIPIFCFDFAPQYISDLLDSILRIYDTCNNSLVKRARAITSVHPATAMNEVDISND VANEGDFDDLAISELKRMSLTPSGVDFAEIKSLIFSDDFLPRIIPLLTNENIFCLLQLSIA SFDINSIEKISYSISLKDSNDLIIVAMINNALVNYGYVEKSKSLLKRAEKLICNVRLRLN NKYPSMPTGTGSPISDSSGIGVRTGGTKEDNFNFGVSDCSGSHLPLKLRDISWVSSI SNLLCSKDLSNSESFHLLSFISSLYSHPFIVSTVLKKFIVAHHILIRMLKSKLHINQAMIS AICQVLNNTCCINQLQQLLMMTDLLQYHMSNDFYSAILDACIRINSPDHLLESVNK YKKFGFHPDLQTYGLLIKFFSSSDNVMECFHLWNEMTSLYGYELNEVTYGCMFDAL VSNNMLDEALSLLKDMKKNSNIKPNTIIYSTLIKGFGQTKQLNKALNIYLTMLDEGV VPNTITYNSIIDACARVGDMNKAANLLEDMLNNNIEPDLITFSTVIKGYCVQSNMD RSLQLLRAMSERGIKPDGILYNSLLDGCVKSGRPWLCQQLWDEMQENGIAPSNFT LTILIKMYGRLGQLDKAFQLMDELPRKYNIQTNTHVYTCLMSACITNGKYKMALDV FNCMNGNGIVPDSKTYETIIFGAIKGRLLYQVIDIIKAAYTLMSRGNGTGGRMNKSI FKIESRILKLFAQKVEASGDPLLLQQAQSLAENLKKFNIILPIRSNLVTQKTQIKKVSNS RAGHYDSFLLKNVTQSLRNDCTNNYRRNSVGATVFANNDGFKDNSVSDFREGINC FGSDDNLNSFKDEHFNAHTQRMHTFASDITCNYRNDERNFQKENRSASGGTTLK GVMWDKDIGGNINNAAYRFDASSIPYSAENAAIGSINSVFGGSYAGNGEDHFLSK NPQYSMQFNPAMVPASNCGNRRGKLKF 52 MAQLAVEELSPFERQELLCVYSSLLLYDDELEISKENINKVLNSAGAKVEPYLPMLFA BMR1_04G05940 KALKGKDLNALFGSVASIGAPVASHAAATTSAAVDAPQAGKAQESNVEEEEDDDD full sequence MGFSLFD 53 MRWKPIYVFTSALIRLFCIFSCNITFSECIRQSHGVDRRNINGLSLCTPTNVLFSTFAC BMR1_02G02565 YIRPSKIGKSYNNLNKYKLGTSSSEVDGNEQSDISSGSDVERGNLIQGKRLKNYYRIL full sequence NLDKYASGEDIKNQYENLIESLKPLENVDSNVIDMINEAYRILSDENTRRIYDELVAK KSLEKESGYNDSNIDQFYHDDGDYFPENLYNVLESDYDFTSDSDEMVLEMSTDDD YSDEDSNEMISLIPKLIKPNGTKLHTTLTIPFERAIMGGNETVTISRLENCKCLENLTTC KSCNGYGLDGKDKLGTGFVSSKECSECGGIGKSRAKKCDLCDNTGQVKVDNATIQ VQVPRNVYDGARLLIRNQGNVYGTNGKAGDLVVTLRVKEHDHMYRMGKNIYSD VTVPYAAAILGTTIKLETCGGVVSLEIPPGTQHGDEIQVPNESIPMKHICRIEVALPKS VDKQERSLLEKIIQLK 54 MDQLKDSIDQSNIDRKAALEAIESFLSSKIQAANAGSIRGKKNPAVNDFNNPPIVQS BMR1_04G06705 YLSEDEGVTSISEYKNGISDPFYNIAVGTNHSISSAKNIPVSYQPNHTDTNRETPLIQR full sequence SIAYFKNKTKFLSKMDTFTSALIPAAITLVITNSAQPLLIFLLRKYGGTPVGAYFFLFPTY LGMICVGLYPTKKPVWKENWIYPGVLAGIDFLHQLIEKAGLLYCGPCLYTVASSSNT LFLALFTSIYLNVKITRNTAISLTIISIAVSFSGSGKLCEINSTHLIGFTLNAFNFVIGEIILK ENKIEGPNLVCIMGFISFISLTLWTCVWTIPNWSTIAHHTEMNVYAIFIILFVLFISNFI RSSVYWILIKRAGSLFTGVLKALRIVIVIVISHILFSHIDPMQRITFTKIFTALLCSTGIVIY SIDNNNKIDNYKNEMKGEREAVEDGEDEKIMVNDDV

[0163] In some embodiments, the compositions include one Bm antigen or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 1, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 2, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 3, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 4, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 5, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 6, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 7, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 8, or one or more antigenic fragments thereof. In some embodiments, the composition includes a Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 9, or one or more antigenic fragments thereof. In some embodiments, the composition includes one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3. In some embodiments, the composition includes one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments thereof. In some embodiments, the composition includes one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0164] In some embodiments, the compositions include one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and also include one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof.

[0165] In some embodiments, the compositions include two Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include two Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof. An exemplary composition includes the following two Bm antigens: BMR1_01G03280 (SEQ ID NO: 1) and BMR1_04G05532 (SEQ ID NO: 2). Another exemplary composition includes BMR1_01G03280 (SEQ ID NO: 1) and BMR1_01G00985 (SEQ ID NO: 3). In some embodiments, the compositions include one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following two Bm antigens: BMR1_01G03280 (SEQ ID NO: 1) and BMR1_02G01760 (SEQ ID NO: 4). In some embodiments, the compositions include two or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments of each of these two antigens. In some embodiments, the compositions include two Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or two or more antigenic fragments thereof.

[0166] In some embodiments, the compositions include three Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments of each of these three antigens. In some embodiments, the compositions include two Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, and one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following three Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2) and BMR1_02G01760 (SEQ ID NO: 4). Another exemplary composition includes BMR1_01G03280 (SEQ ID NO: 1), BMR1_01G00985 (SEQ ID NO: 3), and BMR1_02G01760 (SEQ ID NO: 4). In some embodiments, the compositions include one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and two Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following three Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_03G00365 (SEQ ID NO: 5) and BMR1_03G04695 (SEQ ID NO: 6). In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments of each of these three antigens. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0167] In some embodiments, the compositions include four Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include four Bm antigens that each comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments of each of these four antigens. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and at least one Bm antigen comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition include the following four Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_03G00365 (SEQ ID NO: 5), and BMR1_03G04695 (SEQ ID NO: 6). Another exemplary composition includes BMR1_01G03280 (SEQ ID NO: 1), BMR1_01G00985 (SEQ ID NO: 3), BMR1_03G00365 (SEQ ID NO: 5), and BMR1_03G04695 (SEQ ID NO: 6). In some embodiments, the compositions include four Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments of each of these four antigens. In some embodiments, the compositions include four Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0168] In some embodiments, the compositions include five Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include five Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments of each of these five antigens. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and two Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following five Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), and BMR1_03G04695 (SEQ ID NO: 6). Another exemplary composition includes BMR1_01G03280 (SEQ ID NO: 1), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), and BMR1_03G04695 (SEQ ID NO: 6). In some embodiments, the compositions include five Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include five Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0169] In some embodiments, the compositions include six Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include six Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments of each of these six antigens. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following six Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), and BMR1_03G03430 (SEQ ID NO: 7). Another exemplary composition includes BMR1_01G03280 (SEQ ID NO: 1), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), and BMR1_03G03430 (SEQ ID NO: 7). In some embodiments, the compositions include six Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include six Bm antigens that each comprise an amino acid sequence having at 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0170] In some embodiments, the compositions include seven Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include seven Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments of each of these seven antigens. In some embodiments, the compositions include seven Bm antigens that each comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments of each of these seven antigens. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and four Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and at least one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID NO: 7) and BMR1_04G06070 (SEQ ID NO: 8). Another exemplary composition includes BMR1_01G03280 (SEQ ID NO: 1), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID NO: 7) and BMR1_04G06070 (SEQ ID NO: 8). In some embodiments, the compositions include seven Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0171] In other embodiments, the compositions include eight Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include eight Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments of each of these eight antigens. In some embodiments, the compositions include eight Bm antigens that each comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments of each of these eight antigens. In some embodiments, the compositions include three Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and five Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. An exemplary composition includes the following eight Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID NO: 7), and BMR1_04G06070 (SEQ ID NO: 8). In some embodiments, the compositions include two Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and six Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include eight Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0172] In other embodiments, the compositions include nine Bm antigens, one or more antigenic fragments thereof, or a mixture thereof. In some embodiments, the compositions include nine Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments thereof. In some embodiments, the compositions include the following nine Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID NO: 7), BMR1_04G06070 (SEQ ID NO: 8), BMR1_04G09385 (SEQ ID NO: 9). In some embodiments, the compositions include nine Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0173] In some embodiments, the compositions include one or more (e.g., 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, or 24 or more) Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof. In some embodiments, the one or more Bm antigens each comprise an amino acid sequence having at least 90% sequence identity (e.g., at least 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof. In some embodiments, the one or more Bm antigens each comprise an amino acid sequence having at least 95% sequence identity (e.g., at least 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof. In some embodiments, the one or more Bm antigens each comprise an amino acid sequence having at least 99% sequence identity (e.g., at least 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof. In some embodiments, the one or more Bm antigens each comprise an amino acid sequence of any one of SEQ ID NOs: 1-24. In other embodiments, the compositions include twenty-four Bm antigens or twenty-four or more antigenic fragments thereof. In some embodiments, the compositions include twenty-four or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or twenty-four or more antigenic fragments thereof. In certain embodiments, the compositions include the following twenty-four Bm antigens: BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), BMR1_01G00985 (SEQ ID NO: 3), BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID NO: 7), BMR1_04G06070 (SEQ ID NO: 8), BMR1_04G09385 (SEQ ID NO: 9), BMR1_03G04485 (SEQ ID NO: 10), BMR1_03G01645 (SEQ ID NO: 11), BMR1_03G01960 (SEQ ID NO: 12), BMR1_04G05080 (SEQ ID NO: 13), BMR1_03G00820 (SEQ ID NO: 14), BMR1_01G02100 (SEQ ID NO: 15), BMR1_04G07360 (SEQ ID NO: 16), BMR1_02G02185 (SEQ ID NO: 17), BMR1_04G08260 (SEQ ID NO: 18), BMR1_03G02345 (SEQ ID NO: 19), BMR1_02G02960 (SEQ ID NO: 20), BMR1_01G02545 (SEQ ID NO: 21), BMR1_03G04110 (SEQ ID NO: 22), BMR1_02G02560 (SEQ ID NO: 23), and BMR1_04G05635 (SEQ ID NO: 24).

[0174] In some embodiments, the compositions include one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater), but less than 100% identity, to a reference sequence as set forth herein.

[0175] In some embodiments, a composition comprises one or more of a protein of SEQ ID NO: 49, 50, 51, 52, 53, or 54, or an antigenic variant or fragment of any thereof. In some embodiments, a composition comprises a protein of SEQ ID NO: 49 or an antigenic variant or fragment thereof. In some embodiments, a composition comprises a protein of SEQ ID NO: 50 or an antigenic variant or fragment thereof. In some embodiments, a composition comprises a protein of SEQ ID NO: 51 or an antigenic variant or fragment thereof. In some embodiments, a composition comprises a protein of SEQ ID NO: 52 or an antigenic variant or fragment thereof. In some embodiments, a composition comprises a protein of SEQ ID NO: 53 or an antigenic variant or fragment thereof. In some embodiments, a composition comprises a protein of SEQ ID NO: 54 or an antigenic variant or fragment thereof. In some embodiments of the compositions described in this paragraph, the protein(s) of the composition have at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) identity to the reference sequence noted or to an antigenic fragment thereof.

[0176] In some embodiments, a composition comprises two or more of a protein of SEQ ID NO: 49, 50, 51, 52, 53, or 54, or an antigenic variant or fragment of any thereof. In some embodiments, a composition comprises three or more of a protein of SEQ ID NO: 49, 50, 51, 52, 53, or 54, or an antigenic variant or fragment of any thereof. In some embodiments, a composition comprises four or more of a protein of SEQ ID NO: 49, 50, 51, 52, 53, or 54, or an antigenic variant or fragment of any thereof. In some embodiments, a composition comprises five or more of a protein of SEQ ID NO: 49, 50, 51, 52, 53, or 54, or an antigenic variant or fragment of any thereof. In some embodiments, a composition comprises all five proteins of SEQ ID NO: 49, 50, 51, 52, 53, and 54, or an antigenic variant or fragment of any thereof. In some embodiments of the compositions described in this paragraph, the protein(s) of the composition have at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) identity to the reference sequence noted or to an antigenic fragment thereof.

[0177] In some embodiments, one or more Bm antigen selected from SEQ ID NOs: 49-54, or an antigenic variant or fragment thereof, is comprised within a composition comprising one or more Bm antigen selected from SEQ ID NOs: 1-24, or an antigenic variant or fragment thereof. In some embodiments of the compositions described in this paragraph, the protein(s) of the composition have at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) identity to the reference sequence noted or to an antigenic fragment thereof.

[0178] In some embodiments, the compositions include one Bm antigen that comprises an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater), but less than 100% identity, to a reference sequence as set forth herein.

[0179] Exemplary compositions of the invention are presented in Tables 2-9, below, with each indicated composition comprising the Bm antigens indicated with an “X” or antigenic variants and/or fragments thereof. Accordingly, each indicated composition can comprise Bm antigens (or antigenic variants and/or fragments thereof) that consist of those indicated or, optionally, the compositions can comprise additional components (e.g., additional Bm antigens, antigenic variants, and/or antigenic fragments thereof). In some embodiments, therefore, each indicated composition may be considered as a base or core composition to which additional components (e.g., additional Bm antigens, antigenic variants, and/or antigenic fragments thereof) are optionally added.

[0180] Each composition can also optionally include one or more adjuvant, carrier, diluent, excipient, and/or preservative, e.g., as described herein.

[0181] Furthermore, instead of the indicated Bm antigens (or antigenic variants and/or antigenic fragments thereof), the compositions can each alternatively comprise or consist of corresponding nucleic acid (e.g., mRNA) molecules or modified versions thereof as described herein (see, e.g., Table 10).

[0182] In some embodiments, one or more (e.g., 1, 2, 3, 4, 5, or 6) of the indicated Bm antigens (or corresponding nucleic acids) comprise a sequence that is 100% identical to that indicated in Table 1 (or a corresponding nucleic acid sequence), or an antigenic fragment thereof as described herein (see below). In some embodiments, the one or more (e.g., 1, 2, 3, 4, 5, or 6) Bm antigens or antigenic fragments (or corresponding nucleic acids) are in a combination as set forth in a composition of one of Tables 2-9. In other embodiments, one or more (e.g., 1, 2, 3, 4, 5, or 6) of the indicated Bm antigens (or an antigenic variant and/or fragment thereof, or a corresponding nucleic acid) comprise an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 95%, 97%, or 99%) identical to a sequence in one or more of Table 1 (or a corresponding nucleic acid sequence), or an antigenic fragment thereof as described herein (see below). In some embodiments, the one or more (e.g., 1, 2, 3, 4, 5, or 6) Bm antigens, antigenic variants, and/or antigenic fragments (or corresponding nucleic acids) are in a combination as set forth in a composition of one of Tables 2-9.

[0183] Additional Bm antigens (or corresponding nucleic acid molecules) that can optionally be included in the compositions include those of any one or more of SEQ ID NOs: 4, 8-24, 51-54, or antigenic variants and/or fragments thereof as described herein (or corresponding nucleic acid sequences; see, e.g., Table 10).

[0184] As a specific example, each of the compositions listed below can each optionally include a Bm antigen of SEQ ID NO: 4, or an antigenic variant or fragment thereof.

[0185] In some embodiments, use of the combinations present in the compositions provide additive, synergistic, or otherwise improved results as compared to the use of the individual components alone.

TABLE-US-00002 TABLE 2 Composition No.: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 BMR1_01G03280 X X X X X X X X X X X X X X X X (SEQ ID NO: 1) BMR1_04G05532 X X X X X X X X (SEQ ID NO: 2) BMR1_01G00985 X X X X X X X X X X X X X X X X (SEQ ID NO: 3) BMR1_03G00365 X X X X X X X X (SEQ ID NO: 5) BMR1_03G04695 X X X X X X X X (SEQ ID NO: 6) BMR1_03G03430 X X X X X X X X (SEQ ID NO: 7)

TABLE-US-00003 TABLE 3 Composition No.: 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 BMR1_01G03280 X X X X X X X X X X X X X X X (SEQ ID NO: 1) BMR1_04G05532 X X X X X X X X (SEQ ID NO: 2) BMR1_01G00985 (SEQ ID NO: 3) BMR1_03G00365 X X X X X X X X (SEQ ID NO: 5) BMR1_03G04695 X X X X X X X X (SEQ ID NO: 6) BMR1_03G03430 X X X X X X X X (SEQ ID NO: 7)

TABLE-US-00004 TABLE 4 Composition No.: 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 BMR1_01G03280 (SEQ ID NO: 1) BMR1_04G05532 X X X X X X X X (SEQ ID NO: 2) BMR1_01G00985 X X X X X X X X X X X X X X X (SEQ ID NO: 3) BMR1_03G00365 X X X X X X X X (SEQ ID NO: 5) BMR1_03G04695 X X X X X X X X (SEQ ID NO: 6) BMR1_03G03430 X X X X X X X X (SEQ ID NO: 7)

TABLE-US-00005 TABLE 5 Composition No.: 47 48 49 50 51 52 53 54 55 56 BMR1_01G00985 X X X X X X (SEQ ID NO: 3) BMR1_03G00365 X X X X X X (SEQ ID NO: 5) BMR1_03G04695 X X X X X X (SEQ ID NO: 6) BMR1_03G03430 X X X X X X (SEQ ID NO: 7)

TABLE-US-00006 TABLE 6 Composition No.: 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 BMR1_01G00985 X X X X X X X X X X X X X X X X (SEQ ID NO: 3) BMR1_03G00365 X X X X X X X X X X X X X X X X (SEQ ID NO: 5) BMR1_01G03280 X X X X X X X X (SEQ ID NO: 1) BMR1_03G04695 X X X X X X X X (SEQ ID NO: 6) BMR1_02G01795 X X X X X X X X (SEQ ID NO: 49) BMR1_04G07915 X X X X X X X X (SEQ ID NO: 50)

TABLE-US-00007 TABLE 7 Composition No.: 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 BMR1_01G00985 X X X X X X X X X X X X X X X (SEQ ID NO: 3) BMR1_03G00365 (SEQ ID NO: 5) BMR1_01G03280 X X X X X X X X (SEQ ID NO: 1) BMR1_03G04695 X X X X X X X X (SEQ ID NO: 6) BMR1_02G01795 X X X X X X X X (SEQ ID NO: 49) BMR1_04G07915 X X X X X X X X (SEQ ID NO: 50)

TABLE-US-00008 TABLE 8 Composition No.: 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 BMR1_01G00985 (SEQ ID NO: 3) BMR1_03G00365 X X X X X X X X X X X X X X X (SEQ ID NO: 5) BMR1_01G03280 X X X X X X X X (SEQ ID NO: 1) BMR1_03G04695 X X X X X X X X (SEQ ID NO: 6) BMR1_02G01795 X X X X X X X X (SEQ ID NO: 49) BMR1_04G07915 X X X X X X X X (SEQ ID NO: 50)

TABLE-US-00009 TABLE 9 Composition No.: 103 104 105 106 107 108 109 110 111 112 BMR1_01G03280 X X X X X X (SEQ ID NO: 1) BMR1_03G04695 X X X X X X (SEQ ID NO: 6) BMR1_02G01795 X X X X X X (SEQ ID NO: 49) BMR1_04G07915 X X X X X X (SEQ ID NO: 50)

[0186] In some embodiments, the antigenic fragment may comprise a portion of the Bm antigen of at least 10 (e.g., at least 10, 25, 50, 75, 100, 150, 200, 500, 600, 700, 800, 900, 1000, or more) amino acid residues of a Bm antigen described herein. In other embodiments, the antigenic fragment may comprise a portion of the Bm antigen of at least 100 (e.g., at least 100, 150, 200, 500, 600, 700, 800, 900, 1000, or more) amino acid residues of a Bm antigen described herein. In further embodiments, the antigenic fragment may comprise a portion of the Bm antigen of at least 500 (e.g., at least 500, 600, 700, 800, 900, 1000, or more) amino acid residues of a Bm antigen described herein. Antigenic fragments may be of any length sufficient to induce an immune response when administered to a subject.

[0187] Exemplary Bm antigens useful in conjunction with the compositions, methods, and kits described herein include those for which the amino acid sequence displays at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to one of the foregoing sequences, and in which the sequence changes are conservative amino acid substitutions. Further Bm antigens useful in conjunction with the compositions, methods, and kits described herein include those for which the amino acid sequence has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-50, 2-40, 3-30, 4-25, 5-20, or 10-15) conservative amino acid substitutions with respect to one or more of the foregoing sequences.

[0188] In some embodiments, the Bm antigens used in the compositions of the invention may be purified from the parasite or artificially manufactured molecules, e.g., recombinant proteins, synthetic peptides, proteins or peptides encoded by DNA plasmids or produced by recombinant viruses or bacteria. In some embodiments, the Bm antigens, antigenic fragments thereof, or nucleic acid molecules encoding them (e.g., RNA or DNA molecules) are in purified or isolated form. In some embodiments, the Bm antigens or antigenic fragments thereof (or combinations thereof, e.g., as described herein), are at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% free of other molecules with which they may be naturally associated in nature. In some embodiments, the compositions of the invention are pharmaceutical compositions and do not exist in nature even if specified in general terms, e.g., a composition comprising the antigen or antigenic fragment and a pharmaceutically acceptable carrier or diluent.

[0189] A composition may comprise one or more Bm antigens or antigenic fragments together with other components such as an excipient, preservative, diluent, or carrier. Exemplary excipients include sugars and sugar alcohols, such as lactose, sucrose, glucose, mannitol, and sorbitol, as well as gelatin, cellulose, cellulose derivatives, polyvinylpyrrolidine, starch, and polyethylene glycol. Exemplary preservatives include thimerosal, 2-phenoxyethanol, and formaldehyde. Exemplary diluents include water, saline (e.g., phosphate-buffered saline), and sucrose solutions. Exemplary carriers include human serum albumin.

[0190] A composition may further comprise one or more adjuvants, as readily understood by those skilled in the art. Suitable adjuvants for compositions of the present invention include adjuvants that are capable of enhancing the immune response to the Bm antigens of the present invention (e.g., Bm antigens described herein). Adjuvants are well known in the art (see, e.g., Vaccine Design-The Subunit and Adjuvant Approach, 1995, Pharmaceutical Biotechnology, Volume 6, Eds. Powell and Newman, Plenum Press, New York and London, hereby incorporated by reference).

[0191] Exemplary adjuvants for use in the compositions of the present invention include aluminum salts (e.g., aluminum oxyhydroxide and aluminum hydroxyphosphate) and calcium salts (e.g., calcium phosphate). A well-known example of aluminum oxyhydroxide is Alhydrogel™, whereas a well-known example of aluminum hydroxyphosphate is AdjuPhos™.

[0192] Another adjuvant for use in the compositions of the present invention is an emulsion. An emulsion can be a water-in-oil-in-water emulsion or a water-in-oil emulsion. The oil phase may consist of squalene and squalane mixed in one of several commonly used ratios. A well-known example of such adjuvant oil is Montanide™ ISA-720 (Seppic, Castres, France), which contains both squalene and squalane, with squalene predominating. In addition to the water phase and the oil phase, emulsions contain a surfactant emulsifier. Examples of surfactant emulsifiers include mono- and di-fatty acid (C.sub.12-C.sub.24) esters of sorbitan or mannide, such as sorbitan monostearate, sorbitan monooleate, mannide monostearate, and mannide monooleate. An exemplary water-in-oil emulsion used in the composition of the invention may consist one or more Bm antigens or antigenic fragments thereof dissolved in the water phase and emulsified in Montanide™ ISA-720 using mannide monooleate (Arlacel™ A) as surfactant emulsifier. Oil-in-water emulsion adjuvants include those disclosed in WO 95/17210 and EP 0399842, incorporated herein by reference. An exemplary oil-in-water emulsion is MF59 which uses squalene as adjuvant oil (Chiron Corp; e.g., see, U.S. Pat. Nos. 5,709,879 and 6,086,901).

[0193] Small molecules can be used as adjuvants. Such adjuvants include 7-substituted-8-sulfo-guanosine derivatives and 7-substituted-8-oxo-guanosine derivatives (e.g., 7-allyl-8-oxoguanosine (loxoribine)), as described in U.S. Pat. Nos. 4,539,205; 4,643,992; 5,011,828; and 5,093,318; which are each incorporated herein by reference.

[0194] Lipid products of bacterial origin also can be used as adjuvants, including a monophosphoryl lipid A (MPL) (Corixa Corp.; see, U.S. Pat. No. 4,987,237), and a 3-O-deacylated derivative of MPL (3D-MPL). Cell wall proteoglycans of bacterial origin that can be used as adjuvants include muramyl dipeptide analogues (e.g., as described in U.S. Pat. No. 4,767,842), such as N-acetyl-muramyl-L-threonyl-D-isoglutamine (Thr-MDP; U.S. Pat. No. 4,606,918), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (nor-MDP; CGP 11637), and N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanyl-2-(1′,2′-dipalmitoyl-sn-glycero-3′-hydroxyphosphoryloxy)-ethylamide (MTP-PE; CGP 1983A).

[0195] Other exemplary adjuvants include the saponin fractions derived from the bark of the South American tree Quillaja saponaria Molina (e.g., Quil-A™). Derivatives of Quil-A and methods for its production are described in U.S. Pat. No. 5,057,540. In addition to QS21 (also known as QA21), other fractions such as QS17 (also known as QA17) are described.

[0196] Other exemplary adjuvants include RC-529, CpG oligodeoxynucleotides (Pfizer), SBAS2 (SmithKline Beecham), GM-CSF, Complete Freund's Adjuvant (CFA), and Incomplete Freund's Adjuvant (IFA). Yet another class of exemplary adjuvants consists of glycolipid analogues such as N-glycosylamides, N-glycosylureas, and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid.

[0197] Adjuvant mixtures that can be used in the invention include, e.g., combinations of 3D-MPL and QS21 (see, e.g., EP0671948 B1), oil-in-water emulsions including 3D-MPL and QS21 (see, e.g., WO 95/17210 and PCT/EP98/05714), 3D-MPL formulated with other carriers (see, e.g., EP 0689454 B1), QS21 formulated in cholesterol-containing liposomes (see, e.g., WO 96/33739), and immunostimulatory oligonucleotides (see, e.g., WO 96/02555). Alternative adjuvants include those described in, e.g., WO 99/52549, and non-particulate suspensions of polyoxyethylene ether (see, e.g., UK Patent Application No. 9807805.8).

[0198] Adjuvants are utilized in various amounts, which can vary depending upon the type of adjuvant, the components of the composition (e.g., compositions including one or more Bm antigens or antigenic fragments thereof), and the subject to which the composition is administered. Typical amounts can vary from about 1 μg to about 50 mg per dosage. Those skilled in the art can readily determine appropriate concentrations and amounts to use.

[0199] Babesia Microti Nucleic Acid-Based Compositions

[0200] Compositions of the invention, which can be used, e.g., in the methods and kits described herein, can include one or more nucleic acid molecules (e.g., DNA or RNA (e.g., mRNA)) encoding one or more Bm antigens (or one or more antigenic fragments thereof) and optionally a pharmaceutically acceptable adjuvant, carrier or diluent.

[0201] The nucleic acid molecules can encode any one or more of the Bm antigens or antigenic fragments described above in the subsection entitled “Babesia microti antigen-based compositions” or elsewhere herein. Accordingly, the nucleic acid molecules can encode any one or more (e.g., 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, or 24 or more) of SEQ ID NOs: 1-24 and 49-54, or one or more antigenic fragments thereof (e.g., a fragment of at least 10, 25, 50, 75, 100, 150, 200, 500, 600, 700, 800, 900, 1000, or more amino acids). The nucleic acid molecules can further encode polypeptides having at least 80%, 85%, 90%, 95%, 97%, 99%, or greater sequence identity to any one of SEQ ID NOs: 1-24 and 49-54, or antigenic fragments thereof, consistent with the description provided above.

[0202] In some embodiments, the nucleic acid molecules (e.g., RNA or DNA molecules) are in purified or isolated form. In some embodiments, nucleic acid molecules (e.g., RNA or DNA molecules) are at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% free of other molecules with which they may be naturally associated in nature. In some embodiments, the compositions of the invention are pharmaceutical compositions and do not exist in nature even if specified in general terms, e.g., a composition comprising the nucleic acid (e.g., RNA or DNA) and a pharmaceutically acceptable carrier or diluent.

[0203] The nucleic acid molecules can comprise DNA, RNA (e.g., mRNA), or modified forms thereof. In some embodiments, the nucleic acid molecules comprise DNA that is designed to encode and express an RNA molecule that, in turn, encodes a Bm antigen or antigenic fragment thereof as described herein. Such DNA molecules can optionally be present in the context of a vector (e.g., a plasmid or an expression vector) that is administered to a subject.

[0204] In some embodiments, the nucleic acid molecules comprise an RNA molecule that is administered to a subject. In some embodiments, the RNA comprises one or more modified nucleosides (e.g., pseudouridines and/or 2′-O-methylated nucleosides). In some embodiments, the RNA molecule is non-replicating RNA. In some embodiments, the RNA is self-replicating. In some embodiments, the RNA is present in a lipid nanoparticle. In some embodiments, the RNA is present in an RNA virus (e.g., a retrovirus, lentivirus, alphavirus, or rhabdovirus). In some embodiments, the RNA is introduced into dendritic cells ex vivo, and the dendritic cells are then administered to a subject (e.g., a subject from whom the dendritic cells were obtained).

[0205] Nucleic acid molecule sequences encoding each of SEQ ID NOs: 1-24 and 49-54 are provided below in Table 10 as SEQ ID NOs: 25-48 and 55-60, respectively. DNA coding sequences are shown. As is well known in the art, in the case of RNA molecules, each “T” is replaced with a “U” or an equivalent nucleotide (e.g., pseudouridine). Also as known in the art, nucleic acid sequences can be codon optimized for use in the species in which expression is desired.

TABLE-US-00010 TABLE 10 Nucleic acid sequences encoding exemplary full-length B. microti antigens or their ectodomain SEQ ID NO. Nucleic Acid Sequence Gene ID 25 GATGTATATGAGATATCTTCTGGTAATCCACCCGACATAGAGCCAACATCTACT BMR1_01G03280 TCTCTAGAAACAAATGTAGTTACCAACTATATTCCAGAACCCAATGCGGATTCA ectodomain GAATCTGTACATGTTGAAATCCAGGAACATGATAACATCAATCCACAAGACGCT TGCGATAGTGAGCCGCTCGAACAAATGGATTCTGATACCAGGGTGTTGCCCGA AAGTTTGGATGAGGGGGTACCACACCAATTCTCTAGATTAGGGCACCACTCAG ACATGGCATCTGATATAAATGATGAAGAACCATCATTTAAAATCGGCGAGAAT GACATAATTCAACCACCCTGGGAAGATACAGCTCCATACCATTCAATAGATGAT GAAGAGCTTGACAACTTAATGAGACTAACGGCGCAAGAAACAAGTGACGATCA TGAAGAAGGGAATGGCAAACTCAATACGAATAAAAGTGAGAAGACTGAAAGA AAATCGCATGATACTCAGACACCGCAAGAAATATATGAAGAGCTTGACAACTTA CTGAGACTAACGGCACAAGAAATATATGAAGAGCGTAAAGAAGGGCATGGCA AACCCAATACGAATAAAAGTGAGAAGGCTGAAAGAAAATCGCATGATACTCAG ACAACGCAAGAAATATGTGAAGAGTGTGAAGAAGGGCATGACAAAATCAATA AGAATAAAAGTGGAAATGCTGGAATAAAATCGTATGATACTCAGACACCGCAG GAAACAAGTGACGCTCATGAAGAAGGGCATGACGAAATCAATACGAATAAAA GTGAGAAGGCTGAAAGAAAATCGCATGATACTCAGACAACGCAAGAAATATGT GAAGAGTGTGAAGAAGGGCATGACAAAATCAATAAGAATAAAAGTGGAAATG CTGGAATAAAATCGTATGATACTCAGACACCGCAGGAAACAAGTGACGCTCAT GAAGAAGAGCATGGCAATCTCAATAAGAATAAAAGTGGGAAGGCTGGAATAA AATCGCATAATACTCAGACACCGCTGAAAAAAAAAGACTTTTGTAAAGAAGGG TGTCATGGTTGCAATAATAAGCCCGAGGATAATGAAAGAGACCCGTCGTCGCC TGATGATGATGGTGGCTGCGAATGCGGCATGACGAATCACTTTGTCTTTGACTA CAAGACAACACTCTTGTTAAAGAGCCTCAAGACTGAAACA 26 ATAATTACGGATGGATTGTCCGCTATTGGCTCTGTGGCGAGTGAAGTGGGAAA BMR1_04G05532 TACAGTGAAGGATGTTTCCAGTGAAGCGCTCTTAGGAGAATTACAACAAATTG ectodomain CAGACGGTGGCAAAATTATAAGAGACGGCACTGAAAGCAATTTTGTGAATTCA ATAGCTAATACGGTTATGAAAAATGTAGTTGGCACTGCAGTTCTCAAAGCTTCA TCTGGTATTACACATAATGGTGATTTCGCCTTTTACAACTTTATGTACCCGGAAA ATGATGATTATCCATGGGCATGTATCTGTGATGAATCTGATTATGAAGAGTATA TTAAGGGCAAGAAGGACAAGGTTAGGTGCAGGAACTATATTGATTCATCCTTA CAAAATGCAGTTTTATATTGTAACCCAGCAAATCATAACTCTTCCATAAATGACA ATGCCAATAACAATCCCCCAAAGCAGATTGATAACCATGTGTCCATACCACAAA CAGCGCCAGCAAATCATACCACAGTTTTATCTACGGAAGTCGACACTAATCACA ATGAACAAAAACAACCAAATTCGCCTTCAGTTCCAAGTGAATCTCAAAATTCAG TGTCCGCTCCGAAAGATGAATCTGTTAGTAGCACCGTAGAAGGAGCCAAATCA AGTTCA 27 ACACTTGTATCTAAAATTACAACTCCAAACAATTTACCCGGAATAGATACTTGCT BMR1_01G00985 CGAACTGGGAAGATGTATCAGTGTGTACTACTAAAAACACCAGAAATTGCATTT ectodomain CAGGTGAAGGCAAACCAAAGGATTGTTTTGCGATTGGGAAATCCTTATTTAAA ACATTTCCAAATTGTTATGAAGGTGTTATAATTGATCAAGTCACGTTTTCTGGAT TTGAGACACTAGAAATCCATTATTGCGATATAGATAAGATCTTACACAAAGCAA ATGAAGTTGTTAAATCAATACACGAATTGAAAGAGAAAACAAATCAATTAACC GAGAAAATTAAGGACATACCTGATTTGATTGATAAAGTTATTAAGGTAAATTCG GAAATTTCAAAAATATTTCATCAAGATAAAATTAAACATATGGAAAAGGAGGCC AACGATTTCAAAAACGCCTTGAAAACCACTAGAAACTACATAATCAGTTATGAT TCCTTAGATAAAACCAAGCAAAGCAATCTACTAACTTCACTTGGAAAATTAATG AATAAGATTAAAACAAAACTATCAGAAATGGATAAGACATTACATTCTACACTT GACACAAACAATACCATTATAGATCTTGTCAATAACAATAGTTCACACGTTAAA CATCCTAATGATTTTAACAAAACAATGGAACTCTACAATGAAACTATTACTAAA GCTGATGCGATTAAAAAAAATATTGAAAAACTTAAAGAACATAGGAAAATATC TACTCACAAAACAATATTTTCAAACAATATAGATAAGTTGATTGACAATTTGACA GATTATTTTGAAAATATAAATCGCTCCATTGATGCTGTTAGAGACAAACTTTCCA AATACCAACTTGAAACGGGCAAGATGGTTTTATTGTTTAAGAACGTGAATGAA ATTCAAAAGCATATTAAAAATACAGATATGCATATAAGAACGTGCAATTATGAT TTCTCAGATATCGAACAAAAATACTCACTCATTACTGCAAAAATTACTGTCGAA GATGGACAATCAATCACAACTTCAAATAAATCAACTGTGGATATACCAGAAGA GAAGGTAGATAGGGTGAATGTCAATGTTGACAAAGCAGAGAACTCTGATAATG AAACTTCTCAGGAAAATACATCTGTTAAACCGACTGATCACAAAGAAATTGAGG ATTCAGCTTCCGAAGAAAATGCCATTGGAGAAAATGGTGATTATGATTCAGAT GAAGATATTGATACAAATGACGTTAAAGAAGATCACGAAAATGCAATTGATTC CGAATACACCGTTTCATCGACTGGGGATGTATTAGAAGATGAGGTAGTTGAGG AAAATGCCATTGGAGAAAATGGTGATTATGATTCAGATGAAGATATTGATACA AATGACGTTAAAGAAGATCACGAAAATGCAATTGATTCCGAATACACCGTTTCA TCGACTGGGGATGTATTAGAAGATGAGGTAGTTGAGGAAAATGCCATTGGAG AAAATGGTGATTATGATTCAGATGAAGATATTGATACAAATGACGTTAAAGAA GATCACGAAAATGCAATTGATTCCGAATACACCGTTTCATCGACTGGGGATGTA TTAGAAGATGAGGTAGTTGAGGAAAATGCCATTGGAGAAAATGGTGATTATGA TTCAGATGAAGATATTGATACAAATGACGTTAAAGAAGATCACGAAAATGCAA TTGATTCCGAATACACCGTTTCATCGACTGGGGATGTATTAGAAGATGAGGTAG TTGAGGAAAATGCCATTGGAGAAAATGGTGATTATGATTCAGATGAAGATATT GATACAAATGACGTTAAAGAAGATCACGAAAATGCAATTGATTCCGAATACCTC GTGTCATCGACTGGGGATGTATTAGAAGATGAGGTAGTTGAGGAAAATGCCAT TGGAGAAAATGGTGATTATGATTCAGATGAAGATATTGATACAAATGACGTTA AAGAAGATCACGAGGATGCAATTGATTCCGAATACCTCGTGTCATTGACTGGG GATGTATTAGAAGATGAGGTAGTTGAGGAAAATGCCATTGGAGAAAATGGTG ATCATGATTCAGATGAAGATATTGATATAGAAGAAGTTAACGAAGAGGATCAT GAAGATGCGATTGATTCTGATAACTCCATATCAAATAGCGAAAATGTAGATACT ACACCAACTGAGAATGTAGATACTATACCAACTAAGAATGCAAATACTACACCA ACTAAGAATGCAAATGCTACACCGACTAAGAATGTAGATACTATACCAACTAAG AATGTAGATACTATACCAACTAAGAATGCAAATACTACACCAACTAAGAATGTA GTTACGACACCAACTAAGAATGCAAATACTACACCAACTAAGAATGTAGTTACG ACACCAACTAAGAATGCAAATACTACACCAACTAAGAATGTAGTTACGACACCA ACTAAGAATGCAAATACTACACCAACTAAGAATGTAGTTACGACATCAACTGGA AATGTAAGAACCAAACACACATCGACAAATTCTCATGTTTTAGCTCCGGATACA GACGAATACCCAGCACAAATTTCACAACATAAGACGATTGATAAATATTATCAA TCGTTGGAATTGGAGGATGAAGAAAATGCAGATATATCAAGCTCAGATAAACC AGTTTCTCCAATAAATTTGGAAGATAAAAATTCGACATATGATCATATGCATAA AACCGATAATGTTAAAAGCGCCGGTATTGCTTCATATGAT 28 AACCGCTCTTGTCCAGGAAACAATGGCGTTGGCGGTGGATCTGGTGATAATAA BMR1_02G01760 CAGTGGCATAATTCCAAATGATCCACACCCCTGTTGTAACAATCTTAGACAAAA ectodomain ACCCCAATACCAAACCAAGCCAGAAAATGAACTAGTCAATGATGATAGAGATTT GAACTTTAATAAGATCAGAGGTGGCAAGCAAATCATCACCTTTACTGTCCCTTC CATAGATGATCTCAAGAATAAAAGATTATCCGACTCTGAATTCATTTTATCAGA AAAGGCAAATCCATTGATTTCCTCCGGCGACAGTAAAAACGTTATTGTATTCGA AGTAAAAAACGATAATGAGAAGTTAATGGGTAGTGTTGAAGTTGGTCAATGGG AAGTTACTATCACCACATCATGCATCAGACGTATCGTTATTTTCGATTCCAATGA AGTTTCAGATAACATTCCCATGTATATATATATCGTGGACTACTTTGAAGGAGG TAATAGCACTGTTTCAAAATTCTTTTTCGCGAATAATAGATGGAACGCTGATTTC ACCAATCACACACCTAATGCTGCT 29 TTCCTACTGAACCGCAGCGAATTTAAGTGGTTTAAAGTGGGTCTAATAATTACC BMR1_03G00365 ACGATATTCCCTTTTAAGCATTCATTTGACTATAATTTGACACACATATTTCTATT ectodomain TTCAATATGCACGTTAATATTTTGTGTAAAACCTGTGGATGAGGAGAGCGGTGC CAAAAAGGAGGGATTTGACTTCAAGAAGATGGTGCCAGATAAGTTCAAAAAGT ATACC 30 GATAGTGGTAATTCTTCCCCCCAAACGCCGCCAGAAACTAGCAGTCCTATAAAT BMR1_03G04695 GGTGTAATCGGCGATGAAAATAATGGATTGGAACATTTGAGTAGTTCTGGTCT ectodomain GGAAGTTGATGATAACCTGCCCGAATTACTCAAAACTTCTCCATTTTCAGGCCA AAATTCAGATGTTCAATCTGCTTCAACACCAGTTGAACCCACTACTCCTGTTCAT TCCAATGACCAATCTAATCCTATCACCAATAAAGTTGATACCAATTCTAATGACC ATACTGATATTAAGAATGAAGGTTCATCCCATCGTACTTCATCCAACAATTCTTC TGTCACAACCAATACTAATAATGAGATTAGAAATGGCGGAGGACCATTAGATC AGAATGAAGATAAGGCTGAAGATGAAGGTGAAACTGATGCCGAAGGGAGAG GATGGAATGAGAGAACGAAAAATAAACCTACATTTAATGCCACAAATCGCGAT TTTGTTGATGATAACCTGCCCGAATTACTCAAAACTTCTCCATTTTCAGGCCAAA ATTCAGATGTTCAATCTGCTTCAACACCAGTTGAACCCACTACTCCTGTTCATTC CAATGACCAATCTAATCCTATCACCAATAAAGTTGATACCAATTCTAATGACCAT ACTGATATTAAGAATGAAGGTTCATCCCATCGTACTTCATCCAACAATTCTTCTG TCACAACCAATACTAATAATGAGATTAGAAATGGCGGAGGACCATTAGATCAG AATGAAGATAAGGCTGAAGATGAAGGTGAAACTGATGCCGAAGGGAGAGGAT GGAATGAGAGAACGAAAAATAAACCTACATTTAATGCCACAAATCGCGCTTCTC CCGATGGAATTGGCAAAATGAACATGGAAGAAAAACAGTTGGAGAATTTTATA AATGTATCATCCAACGCTCTTGAATTAGATATCTCAATTGGCCGGGATAATTTTG CTACTAAATTCCTAGCACAACACGTTAATATTTTTGGAGACAGGATAAGCGGCT TGAGTGCGGCGTATGTAGAGGGCTATAATAACTTGGCTAAAATTATGTACAAT AGTCACTCTGTTTTATTTGATAGAAAATTCAATGGAGCAGTTATTTCCGACAATT TGATTGGAAATATTGCAGATTTTGGTTCATACTTCTTAGAGATATCTCCAAATAC AACTAGAACCAATAGAAGTGATTATCTCAAATCAGTAGTACTTTCCAAAGTTCA GTATCTGTTGTCTGCTGATTTTTCCACCACTGACAACATCCAAAGGCTCACAAAT TTGGCACTTGCCCTAGGCTATAACAATGTCAAAGAAAATAATCCTGGCAATTCC CAACATTCAATAACAACCTCCCTCTCAACTGAGCTATTTTGGTCCTTTGGCAACA ATATATTCTTATTTGGACACTTGGCAACTCTAATGCTTGCTTATCTAGAATCTAA TGCATATTTCACATCTGGTGCGACCAGGCCTTTCTTTTCATGGCAAACTCTGGTT TCCACTGGTGGTAATGAGAAATTTGATAAACTGGACTCTATGTGTGGAGTGATT CGTGGATCAAAGTATTCGCGAAAAAACAATGGATTTATCAAGCCACACTACAAA AGATTACGAAGGAAGACTTTGCTCGAAGGTGAACCGCGTTTGTTGTGCAGCAT GCTGGAAGAGGCTTTGGATACTGTGGATAAAGCTATTAAATTTAAGGGCGAAG AGCTAAATTCACAAGGCGCAAATATTGAAAATTCGGTCTCCAATGACATCAACA GTAAACGTTTACAGGCGAAACTTTGCTCAAATTTGAATGATTCACTTATAAACG TGAGCTGTGATTTTAGATCATCAAAATTGGACAAACACAATAAGAAATTAAGA GAGGCATTTGACTTATTATTAGCTTGTGGCAATTTGAACACTGGTAAAAAGGAG GCATTTCCGGAATACTTGAGATTGATCTCTAACCCCTTCGAATACGGCGATATTT TTTCCATGACTATGTGGTGGGATCCTAGGGAGTTTGATGGCAAACAGGGCTGG GTCGAAATATACAAAAAGTTGAGGAAGAATATTATGAAACCTGAACTGAAAAA TGTGGACATGCAACTCAAATACGACTCGGCAATTTCTTATTACAAACAACTGAA GGAATCGGAAACCTACCCCAAGAAAAACATTCCATGGGCTAGATTATACCTTTA CATGTCAGTAATCATGTCAAGATCGAACGCTATGAGTTGGGCTGAGGACGCCC TCCGCTCATTTAGCAATCTATATCGCATGAAACCTTCATTAGTGATGAGAGGGG AAGGGTTAGAGACTTTGCTCAATTACTGCGCTCCTGATCCAGTGGCTTTATCAC ACATATTCCTCTACCACTTTTTGACAAAGAAAGATGCCGGTAAAGATTTGGAAA AAGACTTGAGAAGACTTGAGAAAGGGACACTCCTCTCGCGCATTGTGAATTCA TCGTCAATATTCATACCTAATAAACTAAAGAAATTCCTTAAAATGGGCGCTCGC GGATTTTTCAATAAAAAACTTAACACTTTGAGAGCAAAGAGCACCCTTCTACGA TTATTCCCCAAGAATTTACTACATTCTGCATTGGGCGCAATTGAATTCACCACAC ATTCACTAGCCACGTTACAAATATCTAAGAATATGGATATGTGGGAGAGTTTGG CCCAGACAAAGAATTTAGATGCAGGCGGTTTCCCTGGCGAAATCGATTCACTGT TTAATCATTGGTCGGAAAGTGGTGGATACAGTGGGTATATTACCGGCAAATTA GAGAATGGAGATGATCTAACGGGCGATGATATCAAAAAAATGAACATAAAGG CCCCTATTAACAATGATTCACTCAATTGGCAAAAGTATATCAATAAAAAAATATC CGAGCATTTTGGCAAATTTCTAAACCTTCCATTTATCCAAGCCTCCGGTTCACAA AAGAACTACATATATCAGCTTGTACGGGATAGTAAGGCAAACCTTGACGATAA TTTGGAACAAACTGTGTTCTTTGGCAAAGTGCTTCCCCCAGGAAAAACTAATAA TGTTATTAAGAAATTGAAAAGAATTGCAGATTCATTTACCAGCATGCTGTTACG TTCTTCTGCTCGTCCTGTTGACCATGCTGTGTGGGTTGGAGTGAAAATCAACGT ACCTATTGTAATTCATATTACTAAAAAGTTGTACATGATACAGCGTGATATGCCT AGGAAGGAAGCGTGGAATTTGGAAAGTGCTTTCTTGGACCTGTTGCAGGATCT GGTGATAATGGTTACAAACCCGGGGAAGAGATCTCCGATAGGGTTTGAAACGA TTGGGGGCAATCCTGGATTACCAGAAATTAGCATTAGATACCCTCATATGTCGA TTGAGGAAAGGAAGATTGAATTTCAACATTCACAATGTGCAGATCATTGTATAT CAATTTGGAGATCCCTAATCGCATTTACACTTAACACACTAAACAATCCTGCGGC AATAAAGCAATTTGAGAAATCCTTATCCAGTAATAGTTCTCTAAACGACATGTC GAAGCCCGAATATATCAACAGCTTCAAGTATATACTAAAAGGCGACTCGGTGTT GCATATGTATGATAACATGTTGCCTAGGAAGGTGAAAAGGGAAATAAAGGCAC TAAAGTATGGTAAG 31 CTGCCTGACATTCTATCGCAGAATAACACGTTTAAATCTTTTCTCGAAGTAAATA BMR1_03G03430 ACGTGGATCAGGAAGATTTGATTTGTAATAAGGCACTGTGTAAATCCACTGACT ectodomain CTATCAACAGAAATACAAGTTCTTATTGTTATAAATACAAACTGTGTAGTAAGT GTAGCGTATCCAACGTCCCAGATCACCCTGTTTGCTATCTTCTGGATAATGACCA CAATTACATCCACTTAATGGAGGGGCATTTAGGCTCTCAGCCCATAGGATCAGC GAATAGTCACGATAATTCTTCTCATGACGAACATTCATCGCATTCGAATAATGG AGATATGATGGATGAGCATGAAGAGGAAAATTTTCTGCAGGAATACGAATCAA AATCAATGAAATTCATACCTACTAGCAACATGAGTGACTTTGATCATGCTAGGC GATCTTGTGCCGTGGATTCCAAAGGCAATGTAATGATAAGTGTTAGATTGATCA TCCAATGGTATATGTCAAAGGATAAATCTAATAATCAGCAGCACCATGGCAATG ATGATGATTCTCAAAATTATGACGCAAATTATTTACAACTCACCCCTATGTATTC TGACGACTCTGTTAATTCTTCTATGTTAGAGATGGACCACGACGATAGTGAATC ATCAAATTCGCATAAATCTAGGATGGCAAATATGGCCAAAAACTTCCAAGTTTT GAAAAACATCCATAAAAGTGCAGTTAAGCGTTATAAATCTCCAAAGGCCAAGA TATATCTCATATTTTCTAATCCAAAGATCAACAGCTGTAGACACCCGGTAATATA CAACGGTAAAATCTCCCCCTCAAGCATGTTTGTAGCGAAACTTGAGTCAACAAT ATCACAAATTGATTTGACACAAGATCTGATCAAATCGTCAATAGAAACTATTGT CTCTTGTGAAGCTTGTGATAAGTTAAAATACAACAGTTGTATACAGGTTACCTG TGCCAAAAATACACCAGGCGCAGCGTCTTTAGCTATGGGTAGTGCTGTATACGT TCCAATGACGAATACTACGATTGGAGTAAATGCCCACAACCCTAATGCGGTAGT AGCTGCCGGTATCCCTATGGGTAAAATACCTGTAATCCCCCATCCAGCAGCTAT AAGTGGTGGAAATGTTGGTCATTTGAATAATGGTTTGCACAAGGCGGTTAATA ATGCTGTTATGATGCCAAATGGAACATCATTGCCAGTGCAAAGCGGAGTTGTTA TAAAATCATTATACAATTGTCTCGCTTTTTTACTGACAATTTTGTATCTCAATTTC 32 AACCCTATATTTGCATCTGCAACCTCAGCTCCAAGTAGGAATAGAGCTCAAGAC BMR1_04G06070 ATGACCAAAGCGGAATGTATAGAACTATTAAAAGGCATAGTGAAATCTCAAGA ectodomain GGAAACCAAAATTGTTATGAAGAAGTTGACCTCAGACCTGATAAACAATCCACT GCGCCTAGAACAGGTATATACCAAGGCCAGTCAAATGCAGCCAGAGGATCCTA TGGAGCAATGGGGAGTCACTGTAATTGATCTCGACCATTTGATTGAAAAGTATC AACATGATCCTATTGTGAAGGATTACATTTTGAAGATCATGAATTCGCCCGGCA TAAACGATACAACTCTGAGTGACGATGTACGCAATATTACTATTAGTCAAATAT TAGCTATCCATGAATATATGCTCAGCGAATTGGAGTCTGTAGTCCGCGAATTCA AATCGCTGCAGAACAGACAAACTATGGAGATTAAAACGTTAACTATTGCTGCG CAAGCAATCGTAGCTGCCAAAGTAGAGGAAAAATTCAATTTAACATCAGATCA GGTTGAATCGGCTGTGATAATAAACCATGCCGAATTAACTGCTAGCCATGCATT CACCAGATTGACTATGCAAATGCAGACGGAGATGAGTGAGTTGATTGGGTGCC AATTTCCCGGGTGG 33 AGTACGAATGGTAAGGGGGGTGTAGACTCTGTGTCGAAGAAATCTTTCGTCAT BMR1_04G09385 TGAACTTGAAGACTCCACTTTTGAAAGAAAGACCCAAGCTTCTTCTGGTGGCAC ectodomain TTCTGGTGTATGGTTTGTCAAGTTTTATGCACCATGGTGTGGACATTGTAGATC AATGGAGAATGATTGGAATGAGTTGGCCAATATTTTGGGCAAACAAATTAATG TAGCAAAAATTGATGCTACAAAACACAGTGTTACTGCGAAAAGATTTGGAATTA CAAGTTTCCCAACACTTTTGTTGCTGAAAGATGGAAATTTCTATCAATATGAAAA TAATAATAGAACTGCTGATGCTCTTAAACAATTCGCTTTGCATGGCTATAAACA GGTTAAATCAAAGCCTGTTCCTAAAGAATGGAGTTATTTTGTTCGGTTCAAATTC TTTATCAAATCTGGATTTTATGAAGTTAAGCGCATATACCAGTTAGCATATCCTG GGTTCATAACA 34 ATGGCGAAATTACATGAGAGTACATCAAGTGCAAGTGCTAGCTTCGACCCAGA BMR1_03G04485 GAAGTCGGATTATGACGATACTTATGTTTTAACAGAGACAACGCCAACTTACAT full sequence AAGGCATGGATTTGTTCGAAAGGTCTTTGCTATTTTGTTTGCTCAATTACTAGTG ACCCTTGGATTTTCATTGATCTGTTATTTCTACCGAGAATCTGTTCATTCGTTCAT ATCCAAAAATATCTGGATTTTTCCAACCTTAGCTATATTATCATTTATAACATCCC TTATACTCATATTTTCACCTTCACTCTCTAGGAGATATCCGTTGAATTACGCTATT CTCGTTATAGAAACATTGTATTTCTCATTCATTGTCGGATTGTCATGCGCGTTTA CTAAAAGTCCGACTGCCATAGTATTATCCGTCTCTATTACTCTTGGGATCATTCT TCTTGTTGTTCTGTTCACACTCCAGACCAAAATTGACTTCACTAGATATATTATCT ATTTTATTTTATTTAGTTTTGTAACGTTGGTTTTTGGCTTTATTGGTATCTTTGTCC CATTTGACACCCCTCTCAGGATGTTTTATTACGGTTTAGGCGTACTTGGTTATTC ACTTTGGATGGTACTTGATCTTCAACTGATTATCGGTGGCAAGACTTACGAATG GACGGTTGATGATTACGTCCCTGCATCACTCTCGCTTTATACAGATGTTATTGGA ATTTTCTTAAACGTTCATGGCATGTTTTCTGATAGA 35 ATGACTATAACCTTGAATATAAAGGTTAATTCTGAGACAAATTTTACGGTAGAG BMR1_03G01645 GCTGAACCTTCCTTTACTGTAAAGGAATTAAAGATATTATGTGAATCACAATCG full sequence AATATTGAGGCGCAAAATCAACGCTTAATTTGTAAGGGCAAGCTTTTGAAGGA TACAGACATTCTTTCCGATGTAGGGGCAGTTGATGGTGCCACGGTTTACCTGGT TCGTAGCCAAGTCAACAAAACGCAATCAGCTGCTCCTAAGCAAAATACTGTCCC TCAACCCACATTACAGACTACAAATCAACCTGCTGGTCAAACACAAACGTCTGG ACTTGGATTTCAACAACAAGGGTTTCAGCAAGGATTTTCTGGATCTCAGCAACC AGGATTTCAAGCTAACCCCTTCCAAAGCATGCTTGCTGGTGGATTTCCCAATTTA GATCCCACTCAAATGATGGAGATTTTGAATAGTCCAATGGCACAGGAAGCTAT GCAGAGATTGAGCCAGAATCCAGAAGTTTTGAGGAATATTTTGCAGAACTCAT CTTTGATGACTCCCATGCTTGAACAAAATCCTATGCTATCAGAAATGCTATCAAA CCCGGAATTGATGAGAAGTATGTTGAGACCCGAGGTTTTACAAGCCGGATTGC AAATGCACCAAGCCATGCAGCAGCAGCAACAACAACAACCTGGGACTCAAACC AATCCAATAGGTTCACAAAATCCAGACTTCAGCAACATGATGAGGCAAATGAT GAATGTATTTCAGCAAAATCCATCTGTTGCACAGCCCACAGCACCACAGGTATA TACCGACCCGAGGCCTCCGGCTGAAAGATTTGCAACTCAGCTACAGGCATTGG CTGAGATGGGATTCATTGACACTGAAAAAAATATCACTGCACTTATTGCGACCA ATGGCGATCTCAACGCTACAGTGACCAGGCTGCTTGAATCCAATTTT 36 ATGGAAGAGGCTGAACGCAAATTCAAGGAATTTAATTGGGCCGATAGTCAGG BMR1_03G01960 GATGGCGAATTTACTGGGACAACTTGTATCCAACTCCCCCCTTATCCAAAGTAG full sequence ATAAGTTCAAACGTTCCTGGTTCAAGAGAAACGTAGATTCTAATATATCTTCAA CACCACTGTCTGAGGTTGGCAAACAAACTCAACAAACTACTCCAAATCAATATC GTTCGCAGGGCAACTTTGCTATTTTAACTCTCGAGGCCGGTGTTAGATTGTTGT ACCTGCTTATTACAGCACCTTTATTTGTTCTACCACTAATAGGAGTCAGGCTCAG TAGATATATATACTACCACTACTACATAGACATAGCGCTGTTATTGATCTTTCTA TTGTCTGGCATCGTAAGGGAAAGAGGTCTACCGAAAATGGATTCCGTGTGGCT GGCATCTGCTTTCTATTCAGACATGACACAATATATAATGTATACATGCATCCTG ATGATGTCCGCACCAAGGCCTGTTTATCTGATTTTACCCTTTCTAACTTGTCTAAT CGGGCTAAATTCTCTGGCCGAAACAAATTTATCCAAACTGCCCAAATGGCTTGA AAACATAGTGGGTGAAATATTTAAGTATACTAAGGATAATATATATTGGTTAAT GCAAACTCGTGGCGATGTTGAGTGTTATTTGTTGTTTTATATTGTATTCGGGTTC CTAACGAAATCAAGCGCAGTTATCACTTTAATGGCCTACATAAACTTTATGAAG TTAAGGATTGGCATTGGTGATCCCTTTATAATGTCTGCCTTCTCTAAATTGCATG GCTGCATAGTGAAGTTGTTATCGTATGATATGTTTGGACATATACCTTTGAGGA TGTACTTGAAGATATCAGAGCTCTTAACTAAATATATGTCGGGGCCAAGGCCGC AATAT 37 ATGGAGGACCAAAATACTACAAATGAAAGCATTTCAAATTTGCACATGGAAAA BMR1_04G05080 CTACTTCCCCAAAGATATTTTTTCCAACCTAGATAATCAAAAAAACTTAAAAACA full sequence TATCATTCAAAGACGTTTGAGAAATATTTCGAGTCTGCTGCCAAAGATAATGTT GAAAGGTGTCGTACATCTGCTGTCAAAGAATGGCTGAATAGAAATCTTCCTAGT GAATATAATGAAAGGCACAAGCCCACACTTAAACTAAACCTGAGCCCCAACCAC TTAAACTCAACTTACAACAAACAAATTTCCGATTACACAAGGAATGCCTATAATC GCATAGAACAGTTGAAGAAGCTTCAAGAAGCTTACTCTCTGTTAAGACAGAAA CTACAAGAGAAACGCAGGGCCTCTTGTCATAAGGAGGTCTCTGAGGCAGAGGC TTCAGTTCTTAATACTCAAAGATTGATAATTAGCTTAAAGAGAGAAGACAAAGA TAAAATCGCCACAGAGTTACTTATACAAAATGCAGAAGAGTTAGGTATACCATC CAAAGATTTGGAAACTCTAAACGGCTACACATTTAATGAGGCTCTCAAAACTAT AATCGATATAATTTCTAACATGATAAACAACAAATTTATGACAAATTTGAAAGA TAGGTGTGAATCAGCTAGGCGTAAGGCAGGATCTGAATATCGCGATGAAATGG AAAGGATAAAAGTCGATTTGGACATGTACAAAACAAAGTCTGAAAAACTCGAA TCCACAATATCTACATTGAATTCTTATGCAGATTCTAGCAAACAAAATGCTGAAA AGGTCATGGAATTGCAGCATTCGCTAGAAGATTCCAATAGACAAATTAATCAGC TAAAAGATTCACTGTACAATATGGCCAAAGTTAATGAGGAGTTGGAAAAAAAC GAAGTTAAGCTAGAGGAAAGTTTGGTAGAGTTGGAGAGGTATAAGTTGGAAT CTCAAAAGCTTGAGTCAGTCATTAAAGATTTAGAGCTTTTGAACCAACAAAAAC ATGATAATGAAGAACTCATTAAAATGCTGCATGATGAGCTAGATCAGTGTAAG TCTAAGTCACTGCAATTGAATAAAAAGATTGAAGATCTTGAAAATTCAAACAAG GAAAACCTAATACCCTTGAACAATGAATTGGCCCAGGCTTATCAGAAACTATCC GAATTGGAGCATTCATATGAACAGATTGAACACCAGAAGAATGAAGCAGATAA AAAACTTGAATCTTCAATTGATGAGATTGAGAAACAGAAACAACACTCCGAAG AATTGGAGCAATCCATCACTAAATTGAAACAAACAATTGAAGAAATGGAAAAG GAAACCACGGACCAAGTAAATGATCTGCAAACGTGCCTAATAGATGCGAATTG TAAAATCGAATCGCTAGAGGGAACGATTTCTCAGTTGAAACAGCTAAACTTAG AGTTGGAAGGGGGAGAACATAGGATACAGGAATTACAATCCAAGCTTACCGA ATCAAATTCCACAATTGAAAAACTTGAAAAGACGATCACAGAATTGGAAAATGT GTCTAGTAAATATATCGACTACGATGAGAAGATGGATAATTTGCAAAAGCAGC TGAAAGAATACACTGAAAAGATCACAGTGCTGGAAAACAACGCCTCTGAATTC AACTATAAAGACCAAGCTGAAACGTTGAAGACGGAACTGGATAAGTCGCAACT AAAGATAATGGAACTGGAGACTATGATTAAGGAGAACAGCGAAAAAACGGAA AGAGTGCCATCTCCCAGAAAGGACAACGAGGAGGTTGATAGATTAACTTCGGA AATATTACAGTTGAAGAATCAGGTGGACATTCTGCAAAATGAAAAGACTGACC TTGAACAAAAATTATCACAACAATCTCCCAGAAAGGACAACGAGGAGGTTGAT AGATTAACTTCGGAAATATTACAGTTGAAGAATCAGGTGGACATTCTGCAAAAT GAAAAGACTGACCTTGAACAAAAATTATCACAACAATCTCCCAGAAAGGACAA CGAGGAAGTTGATAGATTAACTTCGGAAATATTACAGTTGAAGAATCAGGTGG ACATTCTGCAAAATGAAAAGACTGACCTTGAACAAAAATTATCACAACAATCTC CCAGAAAGGACAACGAGGAAGTTGATAGATTAACTTCGGAAATATTACAGTTG AAGAATCAGGTGGACATTCTGCAAAATGAAAAGACTGACCTTGAACAAAAATT ATCACAACAATCTCCCAGAAAGGACAACGAGGAGGTTGATAGATTAACTTCGG AAATATTACAGTTGAAGAATCAGGTGGACATTCTGCAAAATGAAAAGACTGAC CTTGAACAAAAATTATCACAAATTAGTGCGGTTATTGAAGAAAATAGACAATAC AAGGAAAAAATCGAATTACTCGAGAGAAAATTGAATGAAATAAATAAAGAGA AACCAAAAGACTCATTTACAAACGTAGAAGTTATCAATGCAGCTTTTGAAGATG TAAGATCCCTCCCAATCAATTCCTCCAATGCCTCTGATTGGACCGCAATGCCCAG TGAGCTGGAGCTGGAAGAGCATAAATTGTACAAAAAAAAATCTAGTAGAAAG GGGAAAAAGAAATCATCAAGGGAGAAGGAGACTAGCAGAAGTGACATATCAT CCAGGTCAACTAGCAGGCACTCAAAGAAGGATAAGCCTACAATCGTTGACAAC AACTCTACTGATGTAGAAGCATCAGATTCAAATGAACAGATGATTAGTGATCCA GTTGAATCGATTACAGACCAGTTGAACTTGGTTAAACAATCAACAATACAACTA ACTGAGCTGGGGTACGACAGCATATCCAACGTTGGGTCGTACTTGTCTGACTAC ATATTTGGCGGTAAT 38 ATGGATGATCTACCCGGTTCATTACATCAATCAACACCAAATGAGAAGCCAATG BMR1_03G00820 GCTCCACCCACAGCACCAAAATCTGCTCCACACGTTCCTATTTCTGTCGAATCAA full sequence AGGAGTTATCAAAAGAAATTCCAAAAGAATCTCCTATGACTAAGGAGGACAAG AAAGACGTGGCCAAGAGTAAAGTTTCTGCTGCTGTAACTGAGAAAAAAGTTGT TAAGGAACCAGTGGTACCTAAAATAACAATTGAGATGAAAAAATTTTCTATGTC CAGAGAATCCACCCAATACTCAATCTTCATTATATTTAACCTTATCTTTGCACTAT TATACATTTTCAAAGTAAGATTGATGGCCATATTTTGCAATCTAATTATTGTGGC TATTTCAATTGGAGCTATCCTTTCCTCCATAGACCCTAATAGACGCAAAGTTGAT GAGACAAATGTTAATATTATATTTATAAGCCCGACAACAGTTTCAGATTTAGCA ATCGTAATCACGGCAAAACTGAACCAGTACATTTCATACTTTAGAAGAATTTTG TTATGGCAGGATTTTATTCTTTCAACCAGATTTACTTTGTGTGTCTACATTATGG GAATCCTTTTCAAAATTATACCGCTGGTTGCTTTAATATATATAATGTGTTGGGC ATTTTATCTTTATATGTTCATATGCAAGGAGATGGCAGATCAGTTGTTGGACATT ATAATGGTTTATTTGAAAAGGGTGTCGGGAAATTTCGACGAGTTCTGCTGCAAT ATCCCCAAGATGAAGGATGTGGGTAAGGAACTG 39 ATGTTTAACGAAAACGAGATCCCTCAGTTCCAGCGCCCTTTCACCCCCTCCAAA BMR1_01G02100 GACACGGAGATTGACACTAGCATCAATTTCCCTGCCAATTCAATTCTAAATAAC full sequence ATATCATTTCAAAAATTATTGGATTGGTTAGATGAATGCACAGAAGGCTTACCA ATCGTGGAAAGTTTTGCGAGACGATTCAACGTTACTAGGGGTCATATAGCGGC AATATTTTCTGCTATATTAATTCTGTACTTTATTTTCGGCTGGAAAATTAACATCT TTTGCAATACAATAGGGTTGGTATATCCAGCATTTAAATCTCATAAGGTTTTACT GATTCATAGAGCCATGACTGAAAGTCCAAAAGCAACAGCTACTATCACAACTG GGGGAAAGGACAAAGAAAATGACACAAACCCTCAAATGCCTACTTGTCTCAAT GGAATCCAAGGGGAAATTATGTTTTGGCTTAGGTACTGGATTGTTTACTCGCTT TATTTATTTATTTCGATATTAATTTTCCCCTTGATATCATGGTTGCCACTAATATC TATAGTTCGGGTTGGTTTTATCCTATATCTCTACCATCCATACACTAGAGGGGCC AACGCGATCTACTACCTCGTAATATCACCTCTGCTAAGCAAAAACCAGAAGATC ATAGAACAGGCCATTGACACCCTCGAAAGGGTTGCGATGGGTGAAATCAGGA AATTTACAGAAAAACAAATGAAGCTACAC 40 ATGGATAGCATTGAAGAGTGTAATAAATTGGTAGATGCGGTGACCAAATTGGC BMR1_04G07360 TACATCATTTGATTACCAAGCGCAAGAATATCTATACAATCTTACCCGCGATGA full sequence AAATGCAATTAACATTGCATTATCCTTTCTATTATCCAATAAATACGTGTTGAAC TATTCAAGCAGTTACAGCAACGAAATTTTACAATATATAACCGATGTTCGTGGC CCAAGCAGTTGTTGCATCTGGGACAATATCCAATTGGACGAAAATACCAGTAG GCATCTGGGCCACATAACGTCTATTTTGTTTAAGGAGCATATGCATATAGTTTT GTGTTTCGACGATGCAAAGCTTATTGCACTTATTGATACATTGGTTACTATTTGG CAATTACAATCAACTATATCACTAGTAACTCAAAGCTGTTTCGCTGATAATGCTA CTGATGATCATATAACGAGAGTTATTTCTATGATTATATTCAAAAAGCCGCAATT ATTAACCCACTTCATCAACATACTAAACACTCCCGAGGTAACTGATAAGTATGT GGCTGATTTCTCAATGAAATTTAAATTAAGAAATTGCGATAGAGATGATATTTA TGTCACAAGGTATAGGCATATGATTGTCTATGTGTTAGCTCAGGTGCTTGAAAA TTTTGTGTCTTCGAACGTTACTGATAAGATATCTTTTTTGCCAATTAACTTCTCAG ATTTAGTCATATTGTCGGGAAATTGTAACAATAGGTATCTTTACTCATGCGCGTT ATTAATTGTAAATTCATTGAACTTTCACATTTCAGAAGAGTTATTACATCAATTA TTGGTAATTGTTGAGAAATCTGGATTTGACTGCGATATACTTGAGATGTGGAAT TTTGCAATCAGTCATTTACAATATTTGAAAGTTGACAATTTCATGATGAAATCTT TCAGGTTAGTCCAAAACGGGCTCATTGAATCCACAAATCCAATAAACATTGTGC CTGTATTAAACGGTATAACAGTATACTATGTTAATAATTCATCAGTTCCAACTGA GATCGTAAGAGCTTACAGGCAATTGCTTTCCGTCGAATCCCTTGACATTCCCATT GAAATCGGTGAGTTATTTGCAGCTGTCCGAAATGCTTGCACTGAAAGTCTGATT ACGTATGATAAAATTGCTTCATTTGTGTCGCAATTTGACATAAGAATGATTTCAA GTAGGTTAATTGAACTTTGCAATCCTAACATGCAATGTTGGTCTTGGTTGAATG TAAATTGTTGTGTAGAAGAATTTCCCACGGATTATGACATATACATTGATTCTAT GAAAAATGTATTTAAAGACCTATTTTTCATCTTACCAGAACAACTTTTAGACACT ATAATAAGTGAGATATTACAATCTGTAAATGAAAATACGGAAACGTCACTAATA GCATTAATTTGCTATGATTGCCTAGAAGTAAGGCATGCATTGGCAATTCTAGAC AAGATTAAATCATTGTTTACGCTGAAATTGTCTTCAAACTACGATTTCATCCTTA CTTGTATGTTTTGCCAATCCATATTTGTGCCTCATTTGCACAGGATAAAAGATAT ATTATTCCAGAGATTTGTTATCAACATGAAAATATCGAATATTTGGTCTAAAAG ACTGGCTAAATGTATAGCAATATTGAACGATAGGGATTCCGTTCATAGCGTGAT TGAATGTGTTCAGTATATATTGGAAACTTCTAAATCCAAGGGTGTATTGTCACA AAATCACTATCCTTCAATTCTATCATTGTCAAATCTTTTAGATACGTTGCCACAAA TGCCTTGTGATGTTAATTTGACTGGATCCAATTATATTTTTTGCAAATGCTTGCT CGCGTTAAGTATTTCTACTAGACAATTATCACAAATATTGCCAAAAATCGCTCTC AATTTGGATATACTATATGAAGGTGATGTGGACAACGATTTGTTTTGTTTATCA ACATCTGATAGCCAAGCTGCAGTTAACTTATTGATGCAACTATATATACAAAAT AAGGTAACCGATATACCTAATGAATTGCACGAGATACGTCACCCCGGGCTTTTA ATGTTATGTAATTTGAATGAAAATTTTGAACAATTCAGGATGAATAAGTGTGTA GAGTTCATGTCAACGGTCAGCCAAGAATCTTGCTGTCACTGTGCATGGGCCTGT ATTGCCTATGCATCTTATGTTATCGAACAGAAATTCAACTTTGAATTTTCAATGG AGATGGTTAAAGTGATATATAGGGTGTTACCATGTTTAATTAAAATGGTTAAGT CCAAGAATGAGCCTTTACATTGGGATTTAGATGCAATTTTGGAGTACAGAATTA ATGAAATACATCCTTCAATTAAGTGTCTAAAGGGGACAATTTGGAATATTTACT ATGATGGTACAGTTAGTGTCGGCTCTGACGCTTGTAAATATTTATCACTAGTAA ATAAATATGCTCCAAGAATCATTAAAAGTTTATCAAATCCAAATGTATTGCAGTT GGTGTATCAAATTTCAATGTGTACTGGATCCATTGAAGTTATAGCAAATAAAAT CGCAATTTCACTA 41 ATGAGCTGCATATTGAAGTGTAACAACGAGGATGAATTGGTTGTGGATGGGGA BMR1_02G02185 AAAACCCAAGGTAGTAGAGTACGTCGAGAAACCATCGGTAATTTACAAGCCTA full sequence CAACCGTTGTCCCCCCTAACAGCCTGATCGAAATTACTGCTCCCAAGGATTTGCC TCAAAATCCAACATTCTTCCCAACCATAGATACATTTTTCGACAATGACGTCAAG CAGATCGTTTTGTTGATGGAATTGCCCGGATTTGTGGCGGGAGATATTGATTTG GAGGTTGGTGAAGGTGAAGTTTGTGTTTGCGGCCCTAGGTCTAAGGAGGAACT ATATGAGAAGTATGGTCAAAATTTAGATATACACATTCGAGAACGAAAGGTTG GCTACTTTTACCGTCGCTTCAAGCTCCCGCACAATGCTCTTGACAACACCGTAAA GGCATCGTATCAAAATGGGATTCTCGAAGTGCGCATTACCTGTACAGAATTTTC ACCGAAAACGCGTGTGGAGATCACATCT 42 ATGAACGGGTCGGTGGAAGAACTATTAAATCGCTTATCGGCGATTAACGACAG BMR1_04G08260 GTGTTATCTGCTGGTGGATGAAATAAAAAATTACATGTCAAACAAACTTTACCA full sequence TGAGTTAACCCTAGCACTCATCGAGTTGTTTACCATGTCTGAAATATCTTGCAAT GACAGACTTCTTTTATTTGAAATGATAGTGCATCCTATCAAAAATGATCTGAACA TTTTGAAGTTCTCACATATTTTACGCCTGTCCTCTGAACATCTAGAGCCTTTAGC GTCACTAGATCAATTGTCTAAATATGACAATTACTTATCAACAGACACTCAAGCC AGTTTTATGATTAAAATTGCAAAGTCATACCACCATACTCGGAATCAATCCTACG ACCAAAGTTTGAAGCTTTTGGAGGAAGTAAAACCTGAGATAGAATCCGGATTT GGCTTGGACATAACGGTAATCTCAGCCTATTACAAAGTGTCAGCGAATCTAAAT AAGGCAACGCACAAATACAATTCATGGTACCAGGACTCACTCATGTACCTAAAC TACACTCCTCTGGATAGTATCAGTCCAACTGAACGTGATGAATTGGCACTGGAT ATAGCAATTGCCTCGATTGCAGCGCCAGATAACTACAATTTTGGTGCTGTTCTA ATTCAGCCACTAATCAACACGTGTTTGAAACAGCACTCCACATTTGGCTGGGTA TACGCAATTTTAATGGCTCTTAATGATGGCGACTTCACACAATACGATGAGATA ATTTCAAAATATAAAGTCCAAATCAGCCATTCCGAATTAAATCATCACAAAGAG CAACTCCAAAGAAAAATTACACTTATGGCATTCCTGAAACTCGTGTTTAGAAAG GCTAAGAAACAACGCATATTTACATTCGAAGAAATATCCCAGAATTGTCGGATT CCAATAGATGAGGTGGAATACTTGCTTCTAAAAGCTATGTGCAACAATGTGGTT AAGGGTAAAATTAACCAGGTTGAGCAGATCGTCAGTTTTACGTGGGTTCAACCT AGGATAATCGACTCAACAAAATTGACAGTTCTCCTAGATGGGGTTAACGAGTG GAATCAACAACTAAAAGCGCTCATAAACAAGCTCAAAGAAATTACTCCAGAGTT ACTAGTGTCG 43 ATGTCGGGACTGTTTGGTCAATCGCAGCAGATTGGTGGTGGATTATTTGGCCA BMR1_03G02345 ATCTAACCAACAGTCTGGGGGAGGGTTATTCGGGTCAACATCGCAACAGCCAA full sequence CCCAAACATGCAGCGGATTATTTGGATCATCTCCAGCTCCCGCAAATAGTAGTA TTTTCGGTTCAAATACACAGTCTGCTGCTTCTAGCGGTGGGATTTTTGGTTCATC CACAGCTCCAGTTAATAGCGGAGGCGGCATTTTTGGTCAATCTAACACTAATGT TAGCAGTGGTAGTGGATTATTTGGCGGTGGAAATACTACAGGTCAATCTGGTG GGGGTATTTTTGGTTCATCAACTACTTCGGCTCCAGCATCAGGAGGAGGGTTAT TCGGCCAAACTGGAACCACTACCAGTGGAGGAGGTGGATTATTTACCTCATCTT TTGCGCCAGCGCCAAGTAGTGGCGGACTATTCGGGCAGCCATCCACACCTGCG ACAAGCGGCACTGGATTGTTTTCTAGTACCAGTACGACTCAACCAAGTTCGGGA GCGGGGCTATTTGGTTCAAGTACTACTCCAGCTAGTGGAAGCGGTGGTCTTTTTT GGTCAACCTAGCACTTCAACGACAACTAGTGGTGGTATTTTTGGTTCATCAACT ACTTCGGCTCCAGCATCAGGAGGAGGGTTATTTGGCCAAACAGGAACCCCTGC CAGTGGAAGCAGTGGCATATTTGGCTCAACAAATACCACAACCTCGGCCTCAG GGACTGGATTGTTCGGTTCGACGTCAACAACTCCACAGCCTGGCAGTGGTAGT GGATTATTTGGCGGTGGAAATACTACAGGTCAATCTGGTGGGGGTATTTTTGG TTCATCAACTACTTCGGCTCCAGCATCAGGAGGAGGGTTATTCGGCCAAACTGG AACCACTACCAGTGGAGGTAATTTATTTGGCACCACCAGCACTACAACACCGGC GCCTGCTAGCGGTGGACTATTCGGTTCTTCTTCTACTACGTCCACAACAACTCCA ACACAAGCAACAACTACAGTAGGAGGGGGAGGGTTGTTTGGCACTGCAAGTG CAACTACTGCGCCGGCGTCTGGTGGATTATTTGGCACCACCAGCACCACAACAC CGGCGCCTGCTAGCGGTGGACTATTCGGTTCTTCTTCTACTACGTCCACAACTCC AACACAAGCAACAACTACAGTAGGAGGGGGAGGGTTGTTTGGCACTGCAAGT GCAACTACTGCGCCGGTGTCTGGTGGATTATTTGGCACCACCAGCACTACAACA CCGGCGCCTGCTAACAACACTACTCCTGCTAACACTACAACTGTGCCAACTGCC ATACTAACAACTAGTACACCGTCCCCTGCTACCGATGGTTTATTTGGATCGACC GACGTTACAACTACTACTGATTCCACAACTAAACTCGTTGGCACTAGCCCTTTTG AAAAACAAACAGATTCGGGGCCGGATGTCACTGCCGCTACTAACGATACGCCT AACGCATTTATCACAGATAAGCCAACAGCTGGAGGAGATCTCAAAGGCCAAGT TGAGTTGTCATTTTCGTCTGTGGAGCATGAATGTGTGCAAGACCTACTTTCTAA CTGGGAGAAGAGAATGGAAGTCAAGATACAAAGGTTTACTGAGTTTGCTCAAG ACATACAGAGGATCGATCGCGATCTAATACTACAAACAGAAAAGTTACAAGTA TTGTTGGATGAGCAAGCAACTGTTCAGGAAAGACAGAACCAAGTACAGGAGAT GATCCAAGTTATTGAGAAGGAACAGCAACAGGTGCTAGAATCGTTGGATATAA TGGATACTGCGCTTGAGACGTTGTTGGGTCCAGATAAGAAAATAACCAGTAAG AGTGGCGAAACTATAGATTTCGTCTCCAACAAATTGCGGGATTTAGAAGCTCAA TTAAAGGCCGCACATGATGTGGTGGATTCTGTGGTTAAAGCTTCGCAACCGGA GCCCCTGGCTAATGTTGCTAAAGTGTTTGCATTCCACCAGGACACTATTGAAAA TATCCAGCTTCAGACATCGGAGATTGAGAAGAAACTTGACGCTATTAAGCAGC AGCAAGCAGTC 44 ATGGCATCGCTGCTGAAAGTATCTCCACAGGACAATATCGAGTTTCCACTGGTG BMR1_02G02960 TTATACACGCCTTTAAATGCGAACTTATTACTGGAAAACTTATCTGGTGTGCATG full sequence TGGCCTTTAAAATCAAGACCACAGCACCCAAGGGCTATCTAGTCCGCCCCTCAA CAGGGACAATTAAACCTGGAGAGGCACTTACTGTTCAAATCATTTTGCAGCCTC TTAGTGAGGTTCCAAATGTGGTCAACGACAGGTTCCTCGTCCAGTGCACTGCCA TCGCAAATGACGAATTGGTTTCCAAGGATTTCTGGACTACACTCGACAAAGCCA GTATCCAAGATCACCGCCTCAATGTAACCTTTAAGAAGGATATTGGTCTCAACA TACAGACAAGCCAATCCAACATTGGCGTCCCGCCTCACATCGCCGCCAGAATTC TCACCCCCTTGGGACCCAATGCAGGCGTTGCAGAACTAAGACAAAAGTACGAG GAGCTAGTATCATACTGTCTAACGGCAGAAAAGCAAAAGGCTGCTCTGGTTAA AGACAACGAGAAACTTCGTCAGCGCCTCCACCTGGGCCCCAACGACCCTGCCTC TGGAAACAAATGGCCCCTAGAAGGTTGGCATCTACCCGTAATGGTGATCATATT AGTAATTATTCTCAAGGCCATTGGCTACTGG 45 ATGTCACAAGGACCTGCTATTGGGATTGATTTGGGAACCACTTACTCATGTGTT BMR1_01G02545 GGCGTTTGGAAAAATGAAACTGTAGAAATTATAGCCAATGATCAAGGCAACCG full sequence TACAACTCCGTCTTATGTTGCCTTCACTGATGTGGAGCGATTGGTTGGCGACGC CGCCAAAAATCAGGATGCTAGAAATCCTGAAAACACAGTTTTTGATGCAAAAA GATTGATAGGGAGAAAGATCAATGATCCCTGCATCCAAAGTGATATAAAACAC TGGCCATTTACTGTTGCGGCTGGACCAAATGATAAGCCTGTGATCAAGGTACAA TTTCAGGGTGAAACTAAATCCTTCCACCCAGAGGAAATATCTTCTATGGTCCTCA CCAAGATGAAGGAAATTGCAGAATCTTATTTGGGAAAGACAATCTCTAATGCT GTTATCACTGTACCCGCTTATTTTAACGATTCTCAACGACAGGCCACTAAGGAC GCTGGTACCATTGCTGGGTTAAATGTTATGCGTATTATCAATGAACCAACTGCT GCCGCAATTGCCTATGGTATGGACAAGAAAGGTACTTCTGAAAAAAATGTGTT GATTTTCGATTTGGGCGGTGGCACTTTCGATGTATCAATTTTAACTATCGAAGA TGGCATTTTTGAGGTAAAGGCCACACAAGGTGATACCCACTTGGGCGGTGAGG ACTTTGACAACAGATTGGTCAACTTTTGCGTAGATGACTTTAAGCGAAAGAATG GCGGGAAGAATATTTCAACCAATAGACGTGCATTACGTAGACTTAGAACACAA TGTGAACGTGCTAAACGCACCTTATCCCACTCAACACAGGCCACGATTGTTGTA GAAGCTATATTTGATGGCATCGACTACAGTTGCAACATCACTAGGGCCAGATTC GAGGAGCTCTGTGCCGAAATGTTCAAAAACACTTTAATCCCAGTCGAAAAAGC CTTAGCTGATGCAGATATGGATAAGAAGCAGATCCATGAAGTGGTACTTGTAG GAGGTTCGACCCGTATCCCTAAGATACAGCAATTGATTAAGGACTTTTTTCAATG GCAAAGAACCCTGCAAATCAATTAACCCAGACGAAGCAGTAGCCTATGGCGCG GCTGTTCAGGCTGCAATTTTAACTGGCGAACAATCTAGCAAGGTCCAAGATTTA CTGTTACTAGATGTCACTCCACTGTCACTAGGACTTGAGACCGCCGGCGGTGTT ATGACCGTGCTGATACCCAGAAATACTACTATCCCCGCCAAGAAGGAACAAGA ATTTACAACCAATGAAAATAACCAAACGGGGGTTATGATCCAGGTCTTCGAAG GAGAACGTTCTATGACATGTGACAACAATTTACTAGGCAAATTCCATTTGACTG GCATACCTCCTGCTCCAAGAGGAGTTCCCCAGATTAAAGTCACCTTTGACATCG ATGCCAATGGTATATTGACAGTGTCTGCTGCCGACAAGTCGACAGGAAAGACT GAACATGTAACTATAACAAATGACAAGGGAAGACTTTCACAGCAAGACATTGA TAGGATGGTTGCTGAAGCAGAGAAGTTTAGGGAAGATGATGAAAAGAAGAAG AGGTGTGTTGAATCCAAGAATGAACTTGAGAACTATTGTTATTCAATGAAAAAT GCCTTGGAAGAGGAGGGTGTTAAATCTAAATTGTCATCTTCTGAGCTTTCCGAG GCTCAGAAACTGTTACAAAACACTTTCAGTTGGATAGAATCTAATCAATTGGCT GAGAAAGAGGAATTTGAAGCTAAACTCAAGGAGGTACAAGCTGTATGTACACC TTTGACTGCTAAATTGTACCAAGCTGGTGGTGGCGTCCCAGGTGGCGCTGCCCC AGGTGGATTTAATGCTGGCGGTGCAGCTCCCTCAGGACCAACTGTGGAAGAAG TTGAT 46 ATGAAACTTATCGCCTGTACCCTTAAGAATGTTGAGACCTGTGTCGAAGTAGAC BMR1_03G04110 CCATCTGACACCGTAGATGCTTTAACCAATAAAATTGGATCGAGCCTGAACAAT full sequence GCTAGTGCCAGCAAAATGCGATTAATCCATGCTGGTAAAATTTTGAAAATGGA ACAAAAGATATCGGACTATTCTGACATCAAGGATGGGGATAAAATTATTGTTCT GTTCAGCAAACAATCCGAAGCAAGTACAATAGCTAATCCTACACCTGCCCCTAC CTCTACTCCCATTGCAGATGCCAACACCAGTCCCCCGAAACCCATCCCTACCACG GACCCTAATGCCTTACTGATGGGCGAGGAGCTAGAAAAAGCCATAAACGGTAT AGTAGAAATGGGTTTTGATGTTGAATCAGTCAAAGCGGCCATGAGCGCAGCAT TCAACAACCCTAACAGGGCTATAGAACTCCTCACGCGTCATGAGGTAGACGTTT CAGACCATGATACGCATCAATCTGTTCAAACGACGGGCGTGTTGGATGAGCTG CGACAGCACCCTATGTTTGAGCAGATGCGGGCGATTGTGCGCAGTAATCCACA GACGCTGCCACAAATTTTATCGCTCATAGGGCAGTCAGACCCATCATTACTCCA AGCCATCACTGAAAATCAGGAAGAATTTATCCAGCTACTGAGTGAACCGGTACT AGGCACAAGTGGTGATTTTATTGACGCCCAGTCTATAACTTTGACACCAGAGGA AATGGAGTCTATAAACAGACTGGAGGGGCTCGGGTTTTCGAGACCGGCAGCTG TCGAGGCATTTTTGGCATGCGATAAAAATGAGGAGATGGCAGCAAATTATTTG CTTGAAAACATAGCAGATTATGTCTCTGACAATGATAAT 47 ATGGATGGACAAACGGAACAACAATTGATTGAGGAAAATATCGAAAGATTTAG BMR1_02G02560 GATACTTTATCAATTGCATTTGGACAACAATGAACCCTCTCCCACCGCTCAATTT full sequence AATTATGCATGTGCTCTAGTCTGCTCCAATCAGCGATCACATAATGACACAGCT ATATATCTCTTAGATGAATTGGTTCGCATTAGATATGAAAGTGAAGAATGTTTTT ATCAACTCGCTCTTGCACATATGAAACGCAGAAGTTTCGTCAAGTCAAAGGAAT ACTTGGATCGTATCATTGCACTGGAGGGTTCTAATCAACGTGTAATGGCACTTA AATCAGTAGTCGTTTCATTACTAGCTCAGGATACTTTCATGGGCGGATTACTTG GCGCCACTGCAGCGTTCGCAATAATTCTCTTCTTCACAATGAAAAGGAATACC 48 ATGAACCAGAATTCACTCTGTTGTTCCAAGGGTTTTACCATGTTTGCAGGTGGT BMR1_04G05635 GCCTTTTTCCTAGTTTCATTTAAGCCGGAAACTGTTATAACGAATCCACTGCTGT full sequence TACGGCCGCTGTTGAATGTGAGCTGGGGGTATATATTTGGATCCCATCTATGG GCAGCAATATCTACCTATAACAAAAAATATTGGGAAAACCGGATAATTCCTGAT TATGCTAATTCACCATCACGGGAGATTATGCAAAGCAGACTTAAGATTAACGAA TCGCGCATTTATCGTATATACCTAGAGAATCTAATCCAAACAAACGTTTTAGCG AATGGGATATTATTAGTTACAACAAGCGCATTGGCGCCTTCAAACAAATTTCTA AGGATTTGCTCGGGAGCAGCACTGCTTTTATCCATAGGAAATGTAGTATTTGCG TTGCCTGAAGACGAAAAGGATGATGATGTGGGAGTTGTAAAGACATCTTCTAC TTCATGTTTCCTGTCTGAAGTACTCTCTTTTTGCACATTCGGCGCCATAGTCCCTT ATGTATTTGCA 55 AGGAACCCACGACACACTAAATTTCACAAAAAACACACTCCAATAACTGACATA BMR1_02G01795 TCACCCACAGCTAATAATTTGGATGATTATGAATTAATTACTTATGGAAATGAC ectodomain GAAGGTCTACACGATGAACCTGGCCTTGGTAGTATAGTTACAGATATCGAGAT AAGGACACCCGCCAATTTTGATGGGACAGCTGGTAATAAGGGGAGAAAGAGC AAGCGCACTGATAAACCAGTGAAAAAGGCAAAGCCAGTGAAAACGAGGAACC CAGTGAACATCACCGAGATAAATAACGCTAATGATGAAGATACTATCGACGCA GACTTAGACGAAGATCTAGAGGATGATACTTATACTGATAAGCCCACCGGTTTC TTTATG 56 TCCATAGACTCACAAAAGTCCGATAATGATGTCGCAAACACTAGTGAAACAAGT BMR1_04G07915 GAGAAATTGAATTATTACGATGCGCGAGATGATTTCCTCCATACTATGGATATG ectodomain GTTAATCTAGTCGGTGGCTCCTGCACTTTGATAGATAAGGCAAATCAGCCCAGT GACTTTAAACAACTACTAAATGCTTCTATCTTCGGCTACGGTAGAATCTCAGCCC TTCTCACCCAAACCAAGTCCATCTACGACGTAACAGTGGCCAGTACATTGGCCG CTGTGTTTGGTAAACTGATGCAAATTAATTTGGATGATGAAGGGCTGGCGGTT GAGCAATGGTCTGCCAGGGTTTGTAGTATGTTGGAGATAGCCGAGGCGAGTCT TCTTAGTACATCATTCAAGATCCTGGCTGATAGGCTTACCAAACACTGTGGGAG GATCGCTGAGGTGTTTTTGTCGCAAAAGGAAAATGATCCCATCGATAAAAACA AATCATCAGATTCTATAAATGATTATTCGTCCGGTGAAGGCGTGGACGTTGTTT GGAGTGTGAGTACGGAATGCCTAATGGAATTCATCGCCCCAAACAGCCCAGGC GGGTTCACTTCTAAATGGACCTTTGTGACATTCAAACACCTACTAATGCAGCTGT CCATCTCAATCATAATGTGTGAATATCAGTTGCGTGATCCAAAATTGTTGGATG ATGAAATTGAAGGCGTAGAAAATTTGTTATTTCGCTCATGGGATGTGCTGGAG CATTATAGCAACATTCAGTTCTACACGCAATTAGATGGTGCATCTGGGATAATG ACTTTTGCCCAAAGCAATCTAATGCCCCTTGTGAAACGGGATGGGGATAAAATT AACGTGTCATGGAACCTACAGAATGAATTTGAAGCTGATCCATCGTCTAATAGC AGTGGGGATTTGGGCTTGGCCGCCGGTGATAATGCTAGCAGCGATGGCGAAA AGCCCGTTGCTACAGACCCACCCTTCTACAGCAGGAGGCCCAGGACCTATAGC ATGTTGTCAGACTATAAAAGGAGGCTTTCTCTTACCTACGAGATGTCTGACGAG GACACGCCTGATGAGGATGATGATTTTGAGCGTGAAGATGAGGAAGTAATAGT TGAGAAGGAAACGGAATCAACTCCTAATAAACAAATTAAAAATGCAAAAAACG TGTTTGGCAGAAGAAAAACTCCGCAAAATAAGGTATTTAGACCTAAACTGTATC CACATGATACTGTATCCACTTCTTCTGTGACTTATGCCATTAAAACCAATAATGA GAATCAAATCCAGTTCAAGTCGGGGGCCGCCCAGCCTATTGACTCAGACATCG ATTCAGTCCCTAGGGCTAAAGCTTCAAATCCATCTATTGACTCAGGCAACGATT CAGTCCCTAGGGCTAAAGCTTCAAATCCATCTATTGACTCAGGCAACGATTCAG TCCCTAGGGCTAAAGCTTCAAACCCATCTAATGGCTCAGACATCGATTCAGTCC CTAGGGCTAAAGCTTCAAATCCATCTAATGGCCCAGGCAACGATTCAGTCCCTA GGGCTCAAGCTTCAAATCCATCTAATGGCCCAGGCAACGATTCAGTCCCTAGGG CTAAAGCTTCAAAACCATCTAATGGCTCAGACATCGATTCAGTCCCTACGGCTC CAGCTTCAAAACCATCTAATGGCTCAGACATCGATTCAGTCCCTACGGCTCCAG CTTCAACGTCCAAATCTGTAAGAGGCACTACCGGAACTGGCAGTAACAGTAAA TGGAGCAGTGTCAGAAACTCAGTGCTGAAGAACAAAACTGAAGAGAATGACA ACAACGAGGGCCCTTCCAAGGCTAGTGGTAGTGCTGGTGGTGGGTTGAAAGG TGAGATATCCTTCTCGGACACAGTATCGATACTCAGGTTCAGGTCAGAACCTCT GCGGTGGACCGAAAATACTAAGGTAGAGGCTAACATGCATAGGAAGATGGTC AATAAGTGCCAGGTGGAGCAGCTTCGTCCCCTCTCAATAGACTACTACAACAAG ATCTCCCCGCCCAACCTGGGCCATCCAGTCATGGGACGGGCCACCGCTAGTTCA TCGTCGACCCTTCTACCAAAGTTCATGGGTATCGGTGCCAAGGTATCCAAAACG TCTAACAACCCTTCGATGGACACGCTGTCAAACTTTTGGGGGATGCAACGCCAC GATAAGGAGCTGTCAGGGATTCGTAAATTGGATAAAACTGTTAGCCAAATGGC CATTCTTGACCGCTTTAGTAGACTAGCTGACACCTGCTGGGATGTTGCCAGTGG GAGGCCTTCAGGGTATATTTCTCCGGAGACCATGTACCGCCTAGGCGGTAACA GGAAAGATGATTACATCCATCATGTAACTAGGGTCTATCCCTTCAATTTAGTTAA GGCCTACCGTTTCTTAGTGACCAAAGAGGAGCCCCAAGTGCAGTCAAATGGGG ACGATAATTTTGAATTCTCCCTCTTTTTACAGGCTCCAGAATTTGTCTCGATTCTA CCCAATGGAGATAGGGCCGAAGCTCTGGTTATTGAACAAAAACTTGTCTCAACT ATTAGGACCCTCAACACTAATAGCACAGAAGACCCACCTATAAGCGTCTGTGGA TACGTTTACAAGCGAAACGACGTGGATAGGGTGCTCATTGGTGAGTTTGGCGT TAAATTACCGTCCACTATCCTAGAACACGTCTATAAAATACATACGCCATACACT ATACTCATTCACGCCAAGTTCACCGATAGCAAGTTCAATAAGCTCAAGGCCGTC ATGCAGTTTTTGCAGGGGACACACTTTGGTGACTTCACTTTAAAATTTGTCTACA AGGGTATGGTGCCCAGCAAAAATGTCGTAAAGGACAGTTGCCATGAGTGTTTG ATAGGTCATTAC 57 ATGGACAACGAATTCACTGATTTCTCTTTGGATAAATTTGGTACCACGGAATATT BMR1_01G01620 ACATTAATAACCATAATCACAATTCAAATGATACTGTAGAAGATCCATTCTATCT full sequence TACACATAACCATGATTCTAATGATAACGTAAAACCGAGCATACTAAACCCTGC TAATGCTAGTTCTTGCATCCCTGCTAGTTATTGGCAGCAGCAAATGGAATACAA CGATTCTCATTTGGACAATTCCCGATCTTCCATGATGAACGAGAATCTCATAATC AAAGAACTGGGCGTCGATGATTCTCCTCAGAATGATAATGAGATAACTTCTATT GATGATATTACTAAACTCACTGAAGGTGAACTCACTACCCATACCCATGAACCA TACAATCTAAATTACGATTCTAAAACGGACCTACAAAATGCATTTGATACATTTT ACCATGATTTTTCACTGTTTACTCCTACGGAAACTTTACCTGAATCACAGCCATG CACTATTGATTCCTCTGGCCACCTTTTCAACCACAAATTTGATATATCAAACAAT GACTCGTATTACCAATCCAACGAATACCTCAACACATTGCCACAATCCTTCGGG CATTGGACCAGAACTTCTCAAACTAACAACTGTTCAATGGAAGATAAGCATCGG GATGATGACAACAATAAATTATCTACCCAGCTTTCCACATTTCTAAATCCAATAA ACTCCGACAACGTGGACAACAGTGGTCATTTATACCTTGATATCAACGCATCGA ATACGATGGCAACAGAGTATATGCACTCAAATCAACCATCTGGCAAACCATTTG ACCCCCTAACCCTTCTCAATAGAGTCAAGTTACGCGATTCAACAGCGCAAATTG CATTGGCGCAGATTTTTAACGAAGCACAAGAACAGAAACAAACATTGAACAAT GTACTGGATTCATTATTTGATAATGTAGGATATGAAGGTAATCTTTTGGAGGGC GACTTCAAATTTCCTTTCATATCGGATAGTTTGTTAACTGCAACTATTTCATATTC AGTAAGGACGGCAAATGACGAAATCCTTTCAATACTTGTATGTTACGCAATCAC TAATAAGGTTAATTTACGTGCAGATTTGGTGGCAGATATAATTGATATTTTCTTC AAATCATTAAGGTACTCTGACGCCTACAAACTCATAGATTATTGTTATAATGACA AAACAAAGCTCGACAGCATCCTCAAAACTGATAATTTTCAGCACATGTTCAACA TGTGCAAGGAAATTACAGTTGATAACAAGATTAGTTTTGAAATATATCAATATT TGTTACAGTGCAATGGTGAAAAGGAGATTTTATGTAAGATAGTTGAATCCATTG ATGAGGCAATTGATTCTGATTCTCATTTGGCTTCACTGCTCAGGACATCATCCAT TCCATTTATTATCAGATTATTTGTGGAAAGGGGGGATTTGAATAAGTTATCATA TTATTTGAAGATATATTTGTCGAAGCCAAGCCCTTCTACACACGATTTGGTTGAG ATAATCGACGTCATACTGGAGACGAATAGAGCCCAACTTCAGTCTGTTGTACAA CAAATATCAGAGTCTAACTCTTTTGATTTGACCATTTTGCTGTATATTTTCACATT TTTGCATTTGAAAAATAAGTCCAATATCATTCATATGATCTACGCCGACGCCATT GATAAGCAAATCCAAAACATTCCATCTGACCTTAAAGCAGTACTTACCAGCCTTT CTATACCAATATTTTGTTTTGATTTTGCGCCTCAGTATATTTCCGACTTGCTAGAT TCAATTCTGAGGATCTATGATACATGCAATAATAGTTTGGTCAAACGCGCCCGG GCCATAACCTCGGTTCATCCTGCAACGGCTATGAATGAGGTCGACATTTCAAAT GATGTGGCAAACGAAGGAGATTTTGATGATTTAGCGATATCCGAGCTGAAACG AATGTCATTGACTCCTTCCGGAGTTGATTTTGCTGAGATTAAATCTTTGATATTT TCGGACGATTTTTTGCCTCGAATCATACCTTTGTTAACGAACGAAAATATATTTT GCCTACTTCAACTATCAATAGCTTCTTTTGACATAAATTCAATTGAAAAAATAAG CTATTCAATCTCGCTTAAGGACAGCAATGATTTGATTATTGTTGCCATGATTAAC AATGCGTTGGTCAACTACGGTTATGTTGAGAAGTCAAAGTCACTGCTTAAAAG GGCAGAGAAGCTGATTTGCAATGTAAGACTAAGGTTGAATAATAAGTATCCAT CCATGCCAACTGGTACTGGTTCTCCAATTAGCGATTCCTCTGGTATTGGGGTCC GCACTGGTGGTACGAAAGAAGATAATTTCAATTTTGGCGTCTCTGACTGTTCTG GTTCACACTTACCATTGAAACTACGTGATATATCATGGGTTTCATCTATAAGTAA CTTGTTGTGTTCCAAAGACCTAAGCAATTCTGAGTCATTTCACCTGTTATCTTTTA TCTCCAGTTTGTACAGTCATCCCTTCATCGTAAGCACTGTGCTCAAGAAGTTCAT TGTGGCGCATCACATTTTGATACGTATGCTCAAAAGTAAATTGCACATAAATCA AGCAATGATATCTGCCATATGTCAAGTATTGAATAATACCTGTTGCATAAATCA ACTGCAACAACTACTTATGATGACCGATTTGTTACAGTACCACATGTCAAATGA CTTTTATTCGGCTATTTTGGATGCTTGTATAAGAATTAATTCACCTGATCACCTTT TAGAGTCTGTTAATAAATATAAAAAATTTGGATTCCACCCTGACCTCCAGACAT ATGGCTTGTTGATCAAATTCTTCAGTTCATCAGACAATGTGATGGAGTGTTTCC ACCTTTGGAACGAAATGACGTCCCTTTACGGTTATGAGCTGAATGAAGTAACCT ATGGTTGCATGTTTGATGCATTAGTCTCCAACAACATGTTGGACGAGGCGTTGA GTTTGCTCAAAGACATGAAGAAGAACTCTAATATTAAGCCAAATACAATTATTT ATTCAACACTTATAAAGGGGTTTGGGCAGACAAAGCAGTTAAACAAGGCGTTG AATATCTATTTGACCATGTTGGATGAAGGAGTAGTCCCCAATACTATTACGTAT AATTCTATAATTGATGCATGTGCTCGTGTTGGGGACATGAATAAAGCTGCCAAT TTGCTTGAGGATATGTTAAACAATAACATAGAACCTGACTTAATTACTTTCTCAA CCGTCATTAAGGGATATTGCGTACAATCTAACATGGATCGCTCCTTGCAACTAC TTAGGGCGATGTCTGAAAGAGGGATTAAACCCGATGGAATACTATACAATTCA CTTCTCGATGGATGCGTAAAATCTGGCAGGCCTTGGTTATGCCAACAACTTTGG GATGAAATGCAGGAGAACGGTATAGCACCAAGTAACTTTACCCTCACTATACTG ATTAAAATGTATGGAAGATTAGGCCAACTAGACAAGGCGTTCCAGCTTATGGA TGAGTTGCCCAGAAAATATAACATCCAAACTAATACGCATGTATATACGTGCCT AATGTCTGCCTGCATCACGAATGGCAAATACAAAATGGCTTTGGACGTGTTCAA TTGCATGAACGGCAATGGCATAGTTCCCGATTCAAAGACTTATGAGACAATAAT ATTTGGCGCAATAAAGGGCCGTTTGCTCTACCAGGTGATCGATATTATCAAGGC TGCCTATACCCTGATGAGCCGAGGTAATGGCACAGGTGGGCGGATGAACAAAT CTATTTTCAAGATAGAATCTAGGATACTTAAGTTGTTTGCACAGAAAGTGGAGG CCAGTGGCGACCCTCTGCTGCTACAACAAGCCCAATCATTGGCAGAGAATTTGA AAAAGTTCAACATCATTCTTCCCATTCGTAGCAATTTGGTCACACAAAAAACACA GATTAAAAAGGTATCTAACAGTAGGGCTGGCCATTACGATTCGTTTTTATTGAA GAATGTTACGCAGTCACTTAGGAATGATTGTACCAACAACTATCGCCGAAACAG CGTTGGTGCCACAGTATTTGCAAATAATGATGGGTTTAAGGATAATAGTGTGA GTGATTTTAGGGAAGGAATAAATTGTTTTGGAAGCGATGATAATTTAAACAGTT TCAAAGATGAACATTTTAACGCACACACGCAAAGAATGCACACTTTTGCAAGTG ACATTACATGCAATTACAGAAATGATGAGAGGAATTTCCAAAAGGAAAACCGG TCGGCCTCCGGGGGAACTACGTTAAAGGGAGTCATGTGGGATAAGGATATAG GTGGTAATATTAACAATGCGGCTTATAGATTTGACGCCTCGTCTATACCATACA GCGCTGAAAACGCTGCTATAGGCTCCATAAACAGCGTGTTCGGGGGTTCATAT GCGGGTAATGGTGAGGACCATTTTTTATCGAAGAACCCGCAGTATTCCATGCA GTTTAACCCCGCCATGGTCCCTGCTTCGAATTGTGGCAATCGCAGGGGTAAGCT TAAATTTTGA 58 ATGGCGCAATTAGCCGTAGAGGAGCTTAGCCCTTTTGAAAGACAAGAACTGTT BMR1_04G05940 ATGTGTATATTCATCACTACTATTGTACGATGATGAATTGGAGATATCTAAGGA full sequence AAACATAAACAAAGTGCTAAACAGTGCCGGTGCTAAGGTGGAGCCCTATCTTC CAATGCTTTTTGCCAAAGCTTTGAAGGGTAAGGATTTGAATGCTTTGTTTGGTT CAGTAGCCTCTATTGGTGCTCCTGTTGCTTCCCATGCTGCTGCCACTACTAGTGC AGCGGTAGATGCGCCTCAGGCTGGAAAGGCCCAGGAATCAAATGTTGAAGAA GAAGAGGATGATGATGACATGGGATTTTCACTCTTTGACTAA 59 ATGAGGTGGAAACCAATTTACGTATTTACATCTGCTTTAATACGCCTCTTTTGCA BMR1_02G02565 TATTTAGTTGTAATATAACATTTTCCGAGTGTATAAGGCAATCGCATGGTGTGG full sequence ATAGGAGGAATATAAATGGTTTGTCTTTATGCACTCCTACCAATGTTCTATTCTC GACTTTCGCATGCTATATACGACCATCAAAGATTGGCAAGAGCTACAACAATTT GAATAAGTATAAACTTGGCACAAGTTCCAGTGAGGTTGATGGTAATGAACAAT CAGATATATCATCTGGTTCTGATGTTGAGCGTGGAAATTTAATACAAGGGAAAA GGCTGAAGAATTACTATCGAATTTTAAATTTGGACAAGTATGCATCTGGAGAAG ACATCAAGAATCAGTATGAAAATCTGATTGAATCACTTAAACCGCTTGAAAATG TAGATTCCAATGTTATAGATATGATAAATGAAGCCTATAGGATCCTATCTGATG AAAATACTCGACGCATTTACGATGAGTTGGTGGCAAAAAAATCTCTAGAGAAG GAAAGCGGATATAATGATAGTAATATTGACCAATTTTATCACGATGATGGTGAT TACTTCCCAGAAAATCTTTACAACGTTTTAGAGTCAGATTACGACTTTACCAGTG ATTCTGACGAAATGGTTCTAGAGATGAGCACAGATGATGATTATTCTGATGAA GATTCTAATGAAATGATCAGCTTGATACCCAAATTGATTAAACCAAACGGAACA AAATTGCATACAACACTTACCATCCCCTTTGAAAGAGCAATTATGGGTGGAAAT GAGACAGTGACAATTTCGAGGCTTGAAAATTGTAAATGTTTGGAAAATTTAACT ACATGTAAGAGTTGCAATGGATATGGTCTGGATGGGAAGGATAAATTGGGAA CGGGATTCGTATCATCAAAGGAATGTTCGGAATGTGGAGGAATTGGTAAATCT AGGGCGAAAAAATGTGATTTATGTGACAATACTGGACAAGTTAAAGTTGATAA TGCAACTATTCAAGTGCAGGTTCCGCGAAATGTATATGACGGCGCCAGGCTTTT GATTAGGAACCAGGGAAATGTATATGGCACTAATGGCAAAGCTGGTGATTTAG TTGTAACTTTACGAGTAAAAGAGCATGATCATATGTATAGAATGGGTAAAAATA TATATTCCGACGTCACAGTGCCATATGCAGCTGCTATACTCGGTACTACTATAAA ATTGGAAACATGTGGAGGAGTTGTATCGCTTGAAATCCCTCCCGGTACTCAACA TGGAGATGAAATACAAGTTCCAAACGAGTCTATTCCCATGAAACACATTTGTAG AATTGAGGTTGCGCTGCCTAAATCTGTAGATAAACAAGAAAGGAGTTTGTTGG AAAAGATAATCCAGCTTAAGTAG 60 ATGGATCAATTAAAAGATTCCATTGATCAATCAAATATTGATCGAAAGGCAGCT BMR1_04G06705 CTGGAGGCTATTGAATCCTTTCTTTCCTCTAAAATACAAGCCGCTAATGCGGGG full sequence AGTATTCGTGGGAAAAAGAATCCAGCTGTTAACGATTTTAATAACCCGCCAATA GTACAGTCATATTTATCCGAGGATGAGGGGGTAACCAGTATATCTGAATATAA AAATGGAATATCCGACCCCTTTTACAATATTGCCGTAGGTACCAATCATTCCATT TCCTCGGCGAAAAATATACCTGTATCGTATCAGCCGAATCACACTGATACAAAT AGAGAAACGCCCCTGATACAACGTAGTATTGCCTATTTTAAAAATAAAACTAAA TTCCTCTCCAAAATGGACACGTTTACCTCGGCGTTGATCCCCGCTGCCATTACCC TGGTCATTACTAACTCAGCACAACCACTACTTATATTCTTGCTTAGAAAATATGG AGGGACTCCGGTGGGTGCCTACTTCTTCCTATTCCCAACCTATCTCGGCATGATC TGCGTCGGCCTATATCCAACCAAAAAACCCGTATGGAAGGAAAATTGGATTTAC CCCGGAGTATTAGCTGGAATTGACTTCTTGCATCAGCTTATTGAAAAGGCTGGG TTGCTATACTGCGGTCCATGCCTATACACTGTGGCCAGCAGCAGCAATACTCTG TTCCTAGCGCTATTTACTTCCATTTATTTAAATGTAAAAATAACTAGAAATACTG CAATTTCATTGACTATTATTTCAATTGCAGTGTCATTTAGTGGTTCGGGAAAATT GTGCGAAATAAACTCAACACATTTGATCGGCTTTACATTGAACGCATTCAACTTT GTGATAGGAGAGATCATACTCAAAGAAAATAAAATCGAAGGCCCAAACCTCGT CTGTATAATGGGATTCATATCCTTTATCTCTCTCACCCTCTGGACCTGCGTTTGG ACCATTCCAAACTGGAGTACAATCGCTCATCATACGGAAATGAATGTATATGCC ATTTTCATTATTTTATTTGTCCTGTTTATATCAAATTTCATACGGTCTTCTGTATAT TGGATACTCATAAAACGTGCTGGATCTCTATTCACAGGTGTGCTAAAGGCGCTC CGAATTGTTATTGTTATTGTAATAAGTCACATTTTGTTCTCCCACATAGATCCCAT GCAGAGGATCACATTCACCAAAATCTTCACCGCTCTGCTGTGTTCAACCGGTAT CGTGATCTATTCAATAGACAACAATAATAAGATTGATAACTATAAGAATGAAAT GAAGGGGGAGAGAGAAGCGGTTGAGGATGGCGAAGACGAAAAAATCATGGT AAATGATGATGTTTAA

[0206] Anti-Babesia Microti Antibody-Based Compositions

[0207] Also provided herein are compositions that include one or more (e.g., 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, or 24 or more) antibodies or antigen-binding fragments thereof which specifically bind to one or more Bm antigens or antigenic fragments thereof. These compositions optionally include a pharmaceutically acceptable excipient, preservative, carrier or diluent.

[0208] In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 1, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 2, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 3, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 4, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 5, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 6, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 7, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 8, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of SEQ ID NO: 9, or one or more antigenic fragments thereof.

[0209] In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-3, or one or more antigenic fragments thereof, and to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 4-9, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-9, or one or more antigenic fragments thereof. In some embodiments, the one or more antibodies bind to one or more Bm antigens that each comprise an amino acid sequence having at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 95%, 97%, 99%, or greater) to the amino acid sequence of any one of SEQ ID NOs: 1-24, or one or more antigenic fragments thereof.

[0210] Antibodies and antigen-binding fragments, variants, or derivatives thereof include, but are not limited to, monoclonal, genetically engineered, and otherwise modified forms of antibodies, including, for example, chimeric antibodies, humanized antibodies, primatized antibodies, heteroconjugate antibodies (e.g., bi-, tri-, and quadri-specific antibodies), and antigen-binding fragments of antibodies including Fab, Fab′, F(ab′).sub.2, Fv, scFv, tandem scFv, diabody, triabody, tetrabody, small modular immunopharmaceutical (SMIP), nanobody or other single domain antibody. Also included are affibodies, isolated CDRs, and a combination of two or more isolated CDRs.

[0211] Antibodies can be generated using any of the numerous methods for making antibodies known in the art. Monoclonal antibodies that specifically bind to one or more Bm antigens can be prepared using standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495-7, 1975; Kohler et al., Eur. J. Immunol. 6:511-9, 1976; Kohler et al., Eur. J. Immunol. 6:292-5, 1976; Hammerling et al., Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981). Antigen-binding fragments can be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact antibodies, or, in certain cases, by chemical peptide synthesis procedures known in the art. Antigen-binding fragments also can be identified by screening a phage display library (Vaughan et al., Nat. Biotechnol. 14:309-14, 1996) using a polypeptide of the invention described above. See, for example, the references cited herein above, as well as Zhiqiang An (Editor), Therapeutic Monoclonal Antibodies: From Bench to Clinic. 1st Edition. Wiley 2009, and also Greenfield (Ed.), Antibodies: A Laboratory Manual. (Second edition) Cold Spring Harbor Laboratory Press 2013, for methods of making recombinant antibodies, including antibody engineering, use of degenerate oligonucleotides, 5′-RACE, phage display, and mutagenesis; antibody testing and characterization; antibody pharmacokinetics and pharmacodynamics; antibody purification and storage; and screening and labeling techniques.

[0212] Useful antibodies can be identified using one of several screening assays, including ELISA, immunoprecipitation or Western blot analysis. In one example, antibodies are assayed by ELISA to determine whether they are specific for the immunizing antigen (e.g., one or more Bm polypeptides as described herein). Using standard techniques, some wells of a plate are coated with the immunogen whereas other wells are coated with irrelevant Bm antigens. An aliquot of the antibody sample is added to each well of the plate. The unbound material is washed, and the bound antibody detected by use of a second antibody specific for the immunoglobulin of the species in which the antibody was generated. Antigen-binding fragments can be screened for utility in the same manner as intact antibodies.

[0213] In some embodiments, the anti-Bm antibodies used in the therapeutic or prophylactic methods of the invention can be purified from cells known to produce monoclonal antibodies, e.g., hybridomas as understood by those of skill in the art. In other embodiments, the anti-Bm antibodies used in the therapeutic or prophylactic methods of the invention can be artificially manufactured molecules, e.g., recombinant antibodies. In some embodiments, a therapeutic or prophylactic antibody may comprise monoclonal antibodies along with other components such as excipient, diluent, or carrier (e.g., human serum albumin). A therapeutic or prophylactic antibody may further comprise preservatives or combinations thereof, as will be readily understood by those of skill in the art.

[0214] Pharmaceutical Formulations

[0215] The Bm antigens, the Bm nucleic acid molecules, and the Bm-specific antibodies described herein can be formulated into pharmaceutical compositions that are biologically compatible and suited for administration to a subject

[0216] Compositions may be administered to a subject in a variety of forms which depend on the route of administration, as will be understood by those skilled in the art. The compositions described herein may be administered by the oral route or a parenteral route, including, for example, the intravenous, intraperitoneal, subcutaneous, intradermal, intramuscular, and topical routes.

[0217] A composition described herein may be orally administered, for example, with an inert diluent or an edible carrier. The composition may be enclosed in hard- or soft-shell gelatin capsules, or compressed into tablets, or incorporated directly with the food of the diet. A composition described herein may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers. Compositions suitable for buccal or sublingual absorption include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, gelatin, and glycerin. Nucleic acid-based compositions can optionally be formulated in a drug delivery vehicle such as, e.g., a lipid nanoparticle or a dendritic cell, in the case of an RNA vaccine. DNA vaccines, e.g., plasmid vaccines, can be formulated in saline or sucrose solutions, as is known in the art.

[0218] A composition described herein may also be administered parenterally. Solutions of a composition described herein can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO, and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2012, 22nd ed.) and in The United States Pharmacopeia: The National Formulary (USP 41 NF 36), published in 2018. The pharmaceutical forms suitable for injectable use include dispersions or aqueous solutions, and powders for the extemporaneous preparation of injectable dispersions or aqueous solutions. In all cases, the forms must be sterile and must be fluid to the extent that they may be easily administered via syringe. Compositions for injectable use may be administered by continuous infusion, single or multiple boluses, or through the use of microneedles. Compositions suitable for topical administration include lotions, creams, ointments, gels, foam, transdermal patches, pastes, and tinctures. Nucleic acid-based compositions, such as DNA vaccines, can be administered by injection (e.g., intramuscular or intradermal injection). DNA vaccine administration can optionally include the use of a gene gun and, optionally, gold or tungsten microparticles onto which the DNA has been absorbed.

[0219] The compositions described herein may be administered to a subject, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the composition, the route of administration, and standard pharmaceutical practice.

Methods

[0220] The invention provides methods for determining whether a subject has natural protective immunity against Bm; immunizing a subject against Bm; determining whether a prophylactic regimen has conferred protective immunity against Bm; identifying a subject who is likely to benefit from an anti-Bm antibody based therapy; treating a subject having babesiosis with an anti-Bm antibody based therapy; and optimizing administration of an anti-Bm antibody regimen. The methods described herein are based on the findings that a) resolution of B. microti infection in cd4-deficient mice requires antibody-producing B cells and antibody class switching, b) such resolution is concomitant with the accumulation of B. microti-specific IgG antibodies in blood, and c) these IgG antibodies target a restricted set of B. microti polypeptides.

[0221] Methods for Monitoring Immune Protection

[0222] The invention provides methods for detecting particular combinations of a subset of Bm-specific antibodies that can serve as indicators of protection against Bm, including protection acquired naturally during the course of an infection with Bm, protection induced by a Bm antigen-containing composition, a Bm antigen-encoding composition, or an anti-Bm antibody composition so as to achieve prophylaxis against Bm, and protection induced by an anti-Bm antibody composition so as to treat a subject experiencing babesiosis.

[0223] The invention provides methods for determining whether a subject has protective immunity against Bm. In certain instances, the methods include the use of immunoassays. In one example, the methods include applying a body fluid sample from a subject to a solid support containing one or more Bm antigens or antigenic fragments thereof (e.g., as described herein); applying an antibody detection agent to the solid support; and determining whether the fluid sample contains IgG antibodies that are specifically reactive to the one or more Bm antigens or antigenic fragments thereof. In certain embodiments, the methods further include identifying the subject as likely to have protective immunity against Bm if the sample from this subject is determined to have a sufficient titer of one or more IgG antibodies that bind to one or more Bm antigens or antigenic fragments thereof, that is, a titer in the fluid sample that is above a cutoff titer.

[0224] The invention also provides methods for identifying a patient experiencing babesiosis as likely to benefit from an anti-Bm antibody-based therapy. In certain instances, the methods include the use of immunoassays. In one example, the methods include applying a body fluid sample from a subject to a solid support containing one or more Bm antigens or antigenic fragments thereof (e.g., as described herein); applying an antibody detection agent to the solid support; and determining whether the fluid sample contains antibodies that are specifically reactive to the one or more Bm antigens or antigenic fragments thereof. In certain embodiments, the methods further include identifying the subject as likely to benefit from an anti-Bm antibody based therapy if the sample from the subject is determined to have an insufficient titer of one or more IgG antibodies specific for one or more Bm antigens or antigenic fragments thereof, that is, a titer in the fluid sample that is below a cutoff titer. In some embodiments, the methods further include administering to the subject an effective amount of a composition comprising one or more anti-Bm antibodies if the subject has been identified as likely to benefit from administration of the one or more anti-Bm antibodies.

[0225] The invention further provides methods for optimizing the administration of an anti-Bm antibody-based therapy to a subject experiencing babesiosis. In certain instances, the methods include the use of immunoassays. In one example, the methods include applying a body fluid sample from a subject to a solid support containing one or more Bm antigens or antigenic fragments thereof (e.g., as described herein); applying an antibody detection agent to the solid support; and determining whether the fluid sample contains antibodies that are specifically reactive to the one or more Bm antigens or antigenic fragments thereof. In certain embodiments, the methods further include administering to the subject an effective amount of a composition comprising one or more anti-Bm antibodies if the sample from the subject is determined to have an insufficient titer of one or more IgG antibodies specific for one or more Bm antigens or antigenic fragments thereof, that is, a titer in the fluid sample that is below a cutoff titer.

[0226] Any of the compositions described herein may be used in conjunction with any of the above-described methods. In certain embodiments, the one or more Bm antigens or antigenic fragments thereof (e.g., as described herein) are provided as an array affixed to a solid phase. In other embodiments, antibody reactivity is determined by ELISA, western blot analysis, or rapid diagnostic tests such as a lateral flow assay, or an assay employing a microfluidic device.

[0227] In some embodiments, the body fluid is a blood sample or a cell-free fraction thereof (e.g., a serum or plasma sample). In certain embodiments, the subject from whom body fluid is acquired was previously immunized with a Bm antigen-containing composition, a Bm antigen-encoding composition, or an anti-Bm antibody composition (e.g., a composition described herein). In certain embodiments, the detection of certain Bm-specific antibodies in body fluids of previously immunized individuals is used to ascertain immune protection against Bm. In other embodiments, the subject from whom body fluid is acquired was previously treated with an anti-Bm antibody composition (e.g., a composition described herein). In some embodiments, the detection of certain Bm-specific antibodies in body fluids of individuals previously treated with therapeutic antibodies is used to ascertain immune protection against babesiosis.

[0228] Methods for Conferring Prophylaxis

[0229] The invention provides methods for immunizing or conferring protective immunity against Bm in a subject who does not experience babesiosis. In some embodiments, the methods include administering to the subject a composition including one or more Bm antigens or antigenic fragments thereof (e.g., as described herein). In some embodiments, the methods include administering to the subject a composition including one or more nucleic acid molecules (e.g., DNA or RNA) encoding one or more Bm antigens or antigenic fragments (e.g., as described herein). In other embodiments, the methods include administering to the subject a composition including one or more antibodies or antigen-binding fragments thereof that specifically bind to one or more Bm antigens or antigenic fragments thereof (e.g., as described herein).

[0230] In some instances, the subject has been determined to be at risk of Bm infection or risk of experiencing babesiosis. In certain instances, the subject has been determined to have a titer of IgG antibodies specific for one or more Bm antigens (e.g., as described herein) that is below a cutoff titer in accordance with the diagnostic methods described herein. In some embodiments, administration of a composition as described herein for prophylaxis against Bm reduces duration and/or severity of a future episode of babesiosis.

[0231] Methods for Treating Babesiosis

[0232] The invention provides methods for treating a subject who experiences babesiosis (e.g., mild or severe, including persistent or relapsing babesiosis). In some embodiments, the methods include administering to the subject an effective amount of a composition comprising one or more anti-Bm antibodies or antigen-binding fragments thereof that are specific for one or more Bm antigens (e.g., as described herein).

[0233] The invention also provides methods for supplementing an immune response against Bm in a subject who experiences babesiosis (e.g., mild or severe, including persistent or relapsing babesiosis). In some embodiments, the methods include administering to the subject an effective amount of a composition comprising one or more anti-Bm antibodies or antigen-binding fragments thereof that are specific for one or more Bm antigens (e.g., as described herein). In certain embodiments, prior to administration, the subject has been determined to have insufficient titers of IgG antibodies specific for one or more Bm antigens, that is, titers that are below cutoff titers for these Bm antigens.

[0234] In some embodiments of any of the above-described methods, treatment reduces duration and/or severity of symptoms of babesiosis. In other embodiments, treatment reduces duration of infection with the etiologic agent of babesiosis. In some embodiments, the etiologic agent of babesiosis is Babesia microti.

[0235] Selection of Subjects

[0236] Subjects who may benefit from the methods described herein are subjects who experience or are at risk of experiencing babesiosis (e.g., mild or severe babesiosis, including persistent or relapsing babesiosis). Patients at risk of experiencing mild babesiosis include otherwise healthy individuals of age 40 years and above. Patients at risk of experiencing severe babesiosis include those who lack a spleen; those who suffer from anatomical or functional hyposplenism; those who are or were recently treated with rituximab or any other antibody that depletes mature B cells, including those diagnosed with a B cell lymphoma or an autoimmune disease; those for whom the CD4 T cell compartment has been depleted, including those experiencing HIV/AIDS or treated with an immunosuppressive therapy for stem cell or solid organ transplantation; and those who are immunosuppressed by treatment of comorbidity, including those who suffer from a malignancy and those who are treated from a chronic inflammatory disorder. Patients at risk of developing mild or severe babesiosis are individuals who are exposed to ticks and those who are transfused with blood products, particularly packed red blood cells.

[0237] Subjects who may be treated using the methods described herein include those who received a diagnosis of babesiosis that was made following the standard and routine diagnostic procedures known in the art. An exemplary diagnostic procedure is the microscopic evaluation of thick or thin blood smears after exposure to the Giemsa stain or the Wright stain. Another exemplary diagnostic procedure is the amplification of Babesia genomic DNA by use of the polymerase chain reaction and of Babesia specific primers. In certain embodiments, a subject has already undergone treatment for babesiosis but such treatment has not been sufficient to achieve cure. In other embodiments, the subject has yet to be treated for babesiosis.

[0238] Doses and Dosages

[0239] A composition of the invention is administered to a subject (e.g., a mammal, such as a human or mouse) in an effective amount, which is an amount that produces a desirable effect in the treated subject. Effective and optimal doses and dosages for the compositions of the invention can be determined using methods known in the art. Single or multiple administrations of the compositions of the invention can be carried out to attain the desirable effect. Doses and dosages can be selected by the treating physician. It is anticipated that optimal doses and dosages will vary with the age, weight, and health of the subject. It is also anticipated that optimal doses and dosages will vary with the mode of administration, that is, a lower amount of the composition will be needed to attain the desirable effect when administered by the intravenous route as compared with other parental routes such as the intradermal, subcutaneous and intramuscular routes.

[0240] Guidance to identify effective and optimized doses and dosages of the composition is provided in the exemplified approach described herein. For example, in the context of prophylaxis, subjects are immunized with varying doses at varying intervals, and are evaluated for the titers of antibodies that are specific for one or more Bm antigens. Immunized subjects also are evaluated for their protection from babesiosis caused by a subsequent challenge with a Babesia species. Such results can be used to optimize doses and dosages required for effective immunization of subjects, e.g., humans, mice and other mammals. Results can be extrapolated by persons having skill in the art.

[0241] In the context of prophylaxis, compositions of the invention are administered to a subject (e.g., a human or mouse) in an amount sufficient to delay, reduce, or preferably prevent the onset of the disorder (e.g., babesiosis). By way of example, a composition comprising one or more Bm antigens or antigenic fragments thereof, or one or more nucleic acid molecules encoding one or more Bm antigens or antigenic fragments thereof, may be administered to a subject at a dose in a range of 1 μg/kg to 1,000 μg/kg (e.g., 1 to 1,000 μg/kg, 5 to 1,000 μg/kg, 10 to 1,000 μg/kg, 1 to 750 μg/kg, 5 to 750 μg/kg, 10 to 750 μg/kg, 1 to 500 μg/kg, 5 to 500 μg/kg, 10 to 500 μg/kg, 1 to 100 μg/kg, 5 to 100 μg/kg, 10 to 100 μg/kg, 1 to 50 μg/kg, 5 to 50 μg/kg, or 10 to 50 μg/kg).

[0242] In therapeutic applications, compositions of the invention are administered to a subject (e.g., a human or mouse) already suffering from babesiosis in an amount sufficient to achieve cure, reduce the severity of one or more symptoms associated with babesiosis, or prevent or reduce the complications of babesiosis. By way of example, a composition comprising one or more anti-Bm antibodies or antigen-binding fragments thereof may be administered to a subject at a dose in a range of 50 mg/kg to 2,000 mg/kg (e.g., 50 to 2,000 mg/kg, 100 to 1,500 mg/kg, 200 to 1,000 mg/kg, 300 to 750 mg/kg, or 400 to 500 mg/kg).

[0243] Combination Treatments

[0244] A pharmaceutical composition including one or more anti-Bm antibodies or antigen-binding fragments thereof that specifically bind one or more Bm antigens as described herein, can be administered alone or in combination with one or more therapeutic agents. For example, a pharmaceutical composition including one or more anti-Bm antibodies or antigen-binding fragments thereof that specifically bind one or more Bm antigens as described herein can be administered in combination with standard-of-care antibiotics used in the treatment of babesiosis. Antibiotic regimens used to treat babesiosis include two-drug regimens (e.g., atovaquone and azithromycin; atovaquone and clindamycin; or clindamycin and quinine), three-drug regimens (e.g., atovaquone, azithromycin, and clindamycin; or atovaquone, proguanil, and azithromycin), four-drug regimens (e.g., atovaquone, azithromycin, clindamycin, and quinine; or atovaquone, proguanil, azithromycin, and clindamycin). In combination treatments, one or more of the therapeutic agents may be administered at a lower dose or dosage than the standard dose and dosage used when administered alone. If combined, therapeutic agents should be administered at doses and dosages that provide a therapeutic effect. Doses and dosages may be determined empirically from combinations and permutations or may be deduced by isobolographic analysis (e.g., Black et al., Neurology 65:S3-S6, 2005).

[0245] Evaluation of Efficacy

[0246] The efficacy of the methods and compositions of the invention in preventing or treating babesiosis can be readily ascertained by those of skill in the art by means of (a) evaluating clinical manifestations associated with Babesia infection, including elevated temperature, chills, sweats, anorexia, headache, or (b) detecting abnormal laboratory parameters associated with Babesia infection, including low red blood counts, low platelet counts, elevated liver enzymes, or (c) monitoring the presence of Babesia parasites by microscopic evaluation of peripheral blood smears or PCR-based amplification of Babesia DNA. Thus, according to the methods of the present invention, a subject shows little to no clinical manifestations and/or few to no laboratory parameter abnormalities when titers of IgG antibodies specific for one or more Bm antigens are above cutoff titers for these Bm antigens.

Kits

[0247] The invention also provides kits or articles of manufacture containing materials useful for the prevention of babesiosis, treatment of babesiosis, and/or monitoring of individuals undergoing prophylactic or therapeutic administration of the compositions of the invention.

[0248] Any of the compositions described herein can be provided in a kit for use in accordance with any of the prophylactic and therapeutic methods described herein. By way of example, a kit of the invention may include one or more Bm antigens or antigenic fragments thereof, as described herein. By way of another example, a kit of the invention may include one or more nucleic acid molecules (e.g., DNA or RNA) that encode one or more Bm antigens or an antigenic fragment thereof. By way of another example, a kit of the invention may include one or more antibodies or antigen-binding fragments thereof that are specific for one or more Bm antigens, as described herein. These kits can include a package insert that instructs a user of the kit, such as a physician, to perform the methods described herein. These kits may optionally include a syringe and a needle or another device for administering the composition.

[0249] Any of the composition comprising of one or more Bm antigens can be provided in a kit for use in accordance with the methods described herein to monitor individuals undergoing prophylactic or therapeutic administration of any one of the compositions of the invention. In one example, such a kit includes (a) one or more Bm antigens or antigenic fragments thereof, as described herein, optionally immobilized on one or more solid supports; (b) an antibody detection reagent; and (c) a package insert comprising instructions for using the one or more Bm antigens and the antibody detection reagent in accordance with any of the methods described herein.

EXAMPLES

[0250] The following examples illustrate certain aspects of the invention and are not to be considered as limiting the scope thereof.

Example 1: Host IgG Antibodies are Required for Resolution of Bm Infection in cd4-Deficient Mice

[0251] Mice expressing the cd4 gene (“WT mice”) or lacking the cd4 gene (“cd4-deficient mice” or “cd4-/- mice”) were infected with Bm and monitored over time for Bm parasitemia, i.e., the frequency of red blood cells infected with Bm (FIG. 1). Cd4-deficient mice experienced higher peak parasitemia than WT mice but mice from both strains resolved the infection. Depletion of B cells, antibody-producing cells, by administration of 18B12, a monoclonal antibody directed against mouse CD20, did not alter the inherent resistance of WT mice but prevented the resolution of Bm infection in cd4-deficient mice (FIG. 1). Administration of 2B8, an irrelevant monoclonal antibody that recognizes human CD20 but not mouse CD20, failed to alter the course of parasitemia in WT mice and in cd4-deficient mice (FIG. 1). The importance of B cells to the resolution of Bm parasitemia in cd4-deficient mice was confirmed by the persistence of Bm parasitemia in cd4-deficient mice that lacked the igh6 gene (FIG. 2).

[0252] In cd4-deficient mice, resolution of Bm parasitemia was concomitant with the accumulation in blood of Bm-specific IgG antibodies, but not of Bm-specific IgM antibodies (FIG. 2). To test the hypothesis that IgG antibodies are critical for resolution of parasitemia, cd4-deficient mice that lack the aicda gene were generated. Lack of AICDA, the enzyme required for antibody class switching, including to the IgG class, prevented full resolution of Bm parasitemia in cd4-deficient mice (FIG. 3). Overall, these results strongly suggest that IgG antibodies are required for full resolution of Bm parasitemia in cd4-deficient mice.

[0253] To assess whether IgG antibodies protect from persistent Bm parasitemia by engaging Fc receptors, cd4-deficient mice that lack fcerlg, the gene which encodes the chain common to all activating Fcy receptors, or fcgr2b, the inhibitory Fcy receptor, were generated. Lack of either receptor did not modify the resolution of Bm parasitemia in cd4-deficient mice (FIG. 4), indicating that the Fc portion of IgG antibodies is dispensable for resolution of Bm parasitemia. To test whether IgG antibodies protect from persistent Bm parasitemia by activating the complement system, cd4-deficient mice that lack c3, the gene that encodes the complement component C3, were generated. Lack of c3 delayed but did not prevent full resolution of Bm parasitemia in cd4-deficient mice (FIG. 5), indicating that the complement component C3 and the downstream effectors of the complement system which include C5 and the terminal membrane attack complex are not required for resolution of Bm parasitemia in cd4-deficient mice. Moreover, Bm parasitemia in C57BL/6 mice that lacked c3 was as low as that in wild-type C57BL/6 mice, indicating that neither the complement component C3 nor its downstream effectors are critical for host resistance to Bm. Taken together, these observations indicate that antibody-mediated neutralization of Bm antigens can protect a host from persistent Bm infection even when the Fc portion of the antibodies is removed or when the antibodies are designed to leave the complement system intact.

[0254] To characterize the IgG repertoire produced by cd4-deficient mice following Bm infection, peripheral blood was collected at times of peak parasitemia, partial resolution, and full resolution (FIG. 6). Peripheral blood was also collected from wild-type mice infected with Bm (FIG. 6). For each blood sample, plasma was separated and probed for IgG reactivity to Bm antigens using microarray chips, as described in Example 2, below.

Example 2: A Few Bm Proteins are Targeted by Host IgG Antibodies in cd4-Deficient Mice

[0255] Proteome Microarray Chip Fabrication and Design

[0256] A large number of Bm genes (˜91% coverage of the LabS1 strain genome) were cloned into the expression vector pXT7. Included were the genes corresponding to SEQ ID NOs: 1-24. Custom polymerase chain reaction (PCR) primers comprising 20-bp gene-specific sequences tagged with 33-bp adapter sequences were used to amplify Bm genomic DNA. These adapter sequences, which flank the target amplicons, were homologous to adapter sequences found at the ends of the linearized T7 expression vector pXT7. Such homology allowed amplicons to be cloned by in vivo homologous recombination in competent DH5a cells. The clones were verified by amplifying the inserted genes using sequence-specific PCR primers and sequencing the resulting amplicons. For protein microarray chip fabrication, Bm proteins were expressed in an E. coli-based cell-free in vitro transcription and translation (IVTT) system (RTS 100 E. Coli HY Kit from BiotechRabbit, Berlin, Germany) according to manufacturer's instructions. Expressed Bm proteins were printed onto nitrocellulose-coated glass AVID slides (Grace Bio-Labs, Inc., Bend, Oreg.) using an OmniGrid Accent microarray printer (DigiLab, Inc., Marlborough, Mass.). Fabricated proteins microarray chips were QC'ed using monoclonal anti-polyhistidine (clone His-1; Sigma-Aldrich, St. Louis, Mo.) and anti-hemagglutinin (clone 3F10; Roche, Indianapolis, Ind.) antibodies.

[0257] Each chip was spotted with 4,333 peptide fragments representing proteins from 3,184 unique Bm genes as well as 176 IgG positive control spots and 61 spotted IVTT reactions without Bm ORFs (IVTT controls). The IgG positive control spots served as an assay control, while the IVTT control spots served as a sample-level normalization factor. For each chip, 3 replicates were printed on 3 nitrocellulose “pads.”

[0258] Plasma Probing

[0259] Plasma samples were diluted 1:100 in an E. coli lysate solution (3 mg/mL) in protein arraying buffer (Maine Manufacturing, Sanford, ME, USA) and incubated at room temperature for 30 min. Chips were rehydrated in blocking buffer for 30 min. Blocking buffer was removed, and chips were exposed to diluted plasma samples using sealed, fitted slide chambers to avoid cross-contamination between pads. Chips were incubated overnight at 4° C. with agitation. Chips were washed five times with TBS-0.05% Tween 20, and exposed at room temperature to biotin-conjugated goat anti-mouse IgM and Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, Pa., USA) diluted 1:500 and 1:200, respectively, in blocking buffer. Chips were washed three times with TBS-0.05% Tween 20 and exposed at room temperature to streptavidin-conjugated SureLight P-3 (Columbia Biosciences, Frederick, Md., USA) in the dark. Chips were washed three times with TBS-0.05% Tween 20, three times with TBS, and once with water. Chips were air-dried by centrifugation at 1,000×g for 4 min and scanned on a GenePix 4300A High-Resolution microarray scanner (Molecular Devices). Spot and background intensities were measured using an annotated grid file (.GAL).

[0260] Protein Microarray Data Analysis

[0261] Raw spot and local background fluorescence intensities, spot annotations and sample phenotypes were imported and merged in the R statistical environment, where all subsequent procedures were performed (www.r-project.org). Foreground spot intensities were adjusted for local background by subtraction, and negative values were converted to 1. All foreground values were transformed using the base 2 logarithm (log 2). The dataset was normalized to remove systematic effects by subtracting the median signal intensity of the IVTT controls for each sample. Given that the IVTT control spots carry the chip, sample and batch-level systematic effects, but also antibody background activity to the IVTT system, this procedure normalizes the data and provides a relative measure of specific antibody binding to non-specific antibody binding (a.k.a. background). For the normalized data, a value of 0.0 indicates that the intensity does not differ from background whereas a value of 1.0 (log 2) denotes an intensity that is twice that of background. Immunoreactive antigens were defined as those for which a mean immunoreactivity of at least 1.0 log 2 (i.e., at least twice that of background) was detected at time of peak infection, time of partial resolution, or time of full resolution of infection.

[0262] Results

[0263] In cd4-deficient mice, as parasitemia resolves, the number of IgG reactive Bm antigens markedly increased (FIG. 7A). Sixteen were IgG reactive at time of peak infection, 35 at time of partial resolution, and 52 at time of full resolution (FIG. 7B).

[0264] In WT mice, at time of full resolution, the IgG antibody repertoire was restricted to a set of 60 Bm antigens (FIG. 8, top panel, left of the vertical dashed line). Of these 60 antigens, only 41 were IgG reactive when plasma was obtained from cd4-deficient mice (FIG. 8, middle panel, left of the vertical dashed line and above the horizontal dashed line). Eleven additional antigens which were not reactive to plasma obtained from WT mice were reactive, although marginally, to plasma obtained from cd4-deficient mice (FIG. 8, middle panel, right of the vertical dashed line). Thus, cd4 deficiency results in the loss of IgG reactivity to 19 Bm antigens but in the gain of IgG reactivity to 11 Bm antigens. Such shift in the repertoire of cognate Bm antigens can be attributed to the fact that absence of CD4 curtails the T cell response to low-affinity antigens while promoting the T cell response to high-affinity antigens.

Example 3: Characterization of Bm Antigens Associated with Protective Immunity

[0265] Sixteen distinct antigens were identified at time of peak infection as exhibiting an IgG reactivity that was above background by greater than 2.0-fold (>1.0 log 2) (FIG. 9). Neutralization of these Bm antigens by IgG antibodies may help curtail the rise in Bm parasitemia. Their gene ID and their name (if unnamed, a brief description of their characteristics) are provided in FIG. 10.

[0266] Sixteen antigens were identified as exhibiting a significant gain in IgG reactivity of greater than 2.0-fold (>1.0 log 2) from time of peak infection to time of partial resolution (FIGS. 11+12). Neutralization of these Bm antigens may help achieve partial resolution of Bm parasitemia. Their gene ID and their name (if unnamed, a brief description of their characteristics) are provided in FIG. 13. Of these 16 antigens, only seven were not identified as immunoreactive at time of peak infection (see hatched bars in FIG. 11; numbers highlighted by a hexagon in FIG. 12; antigen names written in black ink in FIG. 13).

[0267] Ten antigens were identified as exhibiting a significant gain in IgG reactivity of greater than 2.0-fold (>1.0 log 2) from time of partial resolution to time of full resolution (FIGS. 14+15). Neutralization of these Bm antigens may help achieve full resolution of Bm parasitemia. Their gene ID and their name (if unnamed, a brief description of their characteristics) are provided in FIG. 16. Of these 10 antigens, only one was not identified as immunoreactive at time of peak infection or as gaining reactivity from time of peak infection to time of partial resolution (see dotted bar in FIG. 14; number highlighted by a rectangle in FIG. 15; antigen name written in black ink in FIG. 16).

[0268] To characterize the 24 distinct antigens identified as exhibiting IgG reactivity at time of peak infection and/or gaining IgG reactivity from one time point to the next, we analyzed their amino acid sequence for the presence of a signal peptide. We also tested for an inverse relationship between IgG reactivity and Bm parasitemia at times of peak infection and/or partial resolution. Of the 24 antigens, nine exhibit a motif that can act as a signal peptide (FIG. 19). Of the eight antigens that contain a signal peptide and were immunoreactive at time of peak infection and/or had gained reactivity by the time of partial resolution, three displayed an immunoreactivity that was inversely correlated with Bm parasitemia at one of these two time points (FIGS. 17 and 18). These three antigens, namely BMR1_01G03280 (SEQ ID NO: 1), BMR1_04G05532 (SEQ ID NO: 2), and BMR1_01G00985 (SEQ ID NO: 3), are referred to as group #1 antigens (FIGS. 19+20).

[0269] Of the eight antigens that contain a signal peptide and were immunoreactive at time of peak infection and/or had gained significant immunoreactivity by the time of partial resolution, five displayed an immunoreactivity that was not inversely correlated with Bm parasitemia at one of these two time points. These five antigens, namely BMR1_02G01760 (SEQ ID NO: 4), BMR1_03G00365 (SEQ ID NO: 5), BMR1_03G04695 (SEQ ID NO: 6), BMR1_03G03430 (SEQ ID NO: 7) and BMR1_04G06070 (SEQ ID NO: 8), are referred to as group #2 antigens. This group of antigens also includes BMR1_04G09385 (SEQ ID NO: 9), an antigen which contains a signal peptide but for which a significant gain in IgG reactivity was only detected at time of full resolution, thereby precluding the testing of a relationship between IgG reactivity and Bm parasitemia at this time point.

[0270] A third group of antigens comprise the 15 antigens that do not contain a signal peptide but were identified as immunoreactive at time of peak infection or as gaining immunoreactivity from one time point to the next. The gene ID of each of these 15 antigens is provided in FIG. 20. One of these 15 antigens, namely BMR1_04G07360 (SEQ ID NO: 16), displayed an immunoreactivity that was inversely correlated with Bm parasitemia at time of partial resolution of infection (FIG. 18).

[0271] Any of the 24 distinct antigens, which are listed in FIG. 20, may be used individually or in combination as a Bm antigen vaccine to confer protection from babesiosis, or may be targeted by a therapeutic antibody composition to resolve or help resolve babesiosis.

Example 4: Screen of Ifngr1-Deficient Mice for Antibody Reactivity and Further Analysis of cd4-Deficient Mouse Screen

[0272] Experiments were carried out to identify antigens that are or become antibody reactive during the resolution of B. microti infection in a mouse model of interferon gamma receptor type 1 (ifngr1) deficiency. The results of these experiments are shown in FIGS. 21-X.

[0273] FIG. 21 shows that B cells are required for resolution of Babesia microti infection in ifngr1-deficient mice. The rationale is that B cells are required for resolution of infection in this second model as demonstrated by the lack of resolution in ifgnr1-deficient mice in which mature B cells have been depleted by chronic administration of the antibody 18B12 (gray triangles). As expected, the isotype control antibody 2B8 does not prevent the resolution of infection (open triangles).

[0274] FIG. 22 shows an experimental design to probe the antibody response in ifngr1-deficient mice. We collected blood from B. microti infected ifngr1-deficient mice prior to infection (d0) and at three time points following infection, namely at time of peak infection (d16), mid resolution (d24), and full resolution (d35). We also collected blood from B. microti infected wild-type mice at time of full resolution (d22). Plasma was separated from blood and probed for IgG reactivity using B. microti whole proteome arrays.

[0275] FIG. 23 shows that a lack of interferon-gamma activity alters the range of cognate antigens recognized by IgG antibodies.

[0276] FIG. 24 shows the accrual of IgG reactivity during resolution of Babesia microti infection in ifngr1-deficient mice. We selected antigens for which IgG reactivity significantly increases by at least 2-fold between peak infection and mid-resolution (top panel) and/or between mid-resolution and full resolution (middle panel). Given that resolution may unfold only if other antigens are already neutralized, we selected antigens for which IgG reactivity significantly increases by at least 2-fold from prior infection to peak infection (bottom panel). Overall, the screen identified 18 distinct antigens for which neutralization may contribute to resolution of infection in ifngr1-deficient mice.

[0277] FIG. 25 shows the inverse relationship between IgG reactivity and parasitemia at time of mid-resolution. To gain evidence that neutralization of some antigens is effective in driving resolution of infection, we tested for an inverse relationship between IgG titers and parasitemia. No such inverse relationship was observed at time of peak infection. At time of mid-resolution, however, an inverse relationship was noted for two antigens, particularly for BMR1_03g00365.

[0278] FIG. 26 shows a list of candidate antigens identified by the screen of ifngr1-deficient mice. We organized the 18 distinct antigens into three tiers. Tier #1 comprises 2 antigens which are predicted to be exposed to the host and for which an inverse relationship was noted. Tier #2 comprises 4 additional antigens which are predicted to be exposed to the host but for which no inverse relationship was noted. Tier #3 comprises 12 additional antigens which are predicted not to be exposed to the host. Of the 18 distinct antigens, 12 were identified by the screen of cd4-deficient mice but 6 are unique to the screen of ifgnr1-deficient mice. Of these 6 antigens, 2 belong to tier #2 whereas 4 belong to tier #3.

Example 5: RNA Vaccines

[0279] RNA molecules encoding one or more of the Bm antigens described herein (or one or more antigenic variants and/or fragments thereof) are generated using standard methods (e.g., in vitro transcription of DNA templates) and formulated for administration to subjects. Optionally, modified nucleosides are used in the synthesis of the RNA molecules to reduce immunogenicity and/or to increase stability. RNA molecules are administered to subjects, e.g., by injection of lipid nanoparticles comprising the RNA.

Example 6: DNA Vaccines

[0280] DNA vaccines can be prepared using expression vectors that are engineered to include sequences encoding one or more of the Bm antigens described herein (or one or more antigenic variants and/or fragments thereof). In addition to the antigen coding sequence(s), the vectors can include promoter sequences (for example, a viral promoter, e.g., a Rous Sarcoma Virus (RSV) promoter, a cytomegalovirus (CMV) immediate early promoter, or an SV40 promoter), a polyadenylation/transcription termination signal, and optionally other standard vector sequences, as are known in the art. The vectors can be mono- or poly-cistronic, as is known in the art. DNA vaccines can be administered to subjects by injection (e.g., intramuscular or intradermal injection), gene gun, or mucosal delivery.

OTHER EMBODIMENTS

[0281] Various modifications and variations of the described invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention.

[0282] Other embodiments are within the scope of the claims.